Botulinum toxin type A
Protein / enzyme biologic targets BCL11A, SNAP25, TGFB1, TRPV1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 38 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | Xeomin | — | 2011-07-20 – 2026-06-25 | fda.gov ↗ |
| Label expansions (20) | US (FDA) | BOTOX COSMETIC | — | 2000-12-21 – 2024-10-18 | fda.gov ↗ |
| Label expansion | US (FDA) | DAXXIFY | — | 2023-08-11 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | DYSPORT | — | 2015-07-15 – 2023-01-12 | fda.gov ↗ |
| Approved | EU (EMA) | Nuceiva | — | 2019-09-27 | europa.eu ↗ |
| Approved | US (FDA) | BOTOX COSMETIC | — | 1991-12-09 | fda.gov ↗ |
Trials 675 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 018 trials | ||||||
| Phase 0 | NCT07640035 | Jul → Dec 2026 expected | bruxism | Bilecik Seyh Edebali University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06785844 | Jul 2025 → Sep 2030 expected | — | Shaare Zedek Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05997043 | Aug 2023 → Jul 2024 | Parkinson disease, overactive bladder | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06349733 | Mar → Oct 2023 | — | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 0 | NCT06437912 | Mar → Oct 2023 | — | Dezhou Hospital Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 0 | NCT05485207 | Apr 2022 → Feb 2025 | interstitial cystitis | Stanford University | Unknown | No outcome recorded |
| Phase 0 | NCT05330078 | Mar 2022 → May 2023 | keloid | University of California, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT04984317 | Feb 2022 → Dec 2026 | female stress incontinence | Northwell Health | Suspended | No outcome recorded |
| Phase 0 | NCT04939909 | Jul → Dec 2021 | benign essential blepharospasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT04715048 | Jan 2021 → May 2025 | — | University of Southern California | Unknown | No outcome recorded |
| Phase 0 | NCT04467450 | Jun → Nov 2020 | bursitis | Benha University | Unknown | No outcome recorded |
| Phase 0 | NCT05463822 | Jun 2019 → Sep 2021 | overactive bladder | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT03186547 | Jun 2017 → Jun 2018 | — | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT03346252 | May 2017 → Mar 2021 | headache disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 0 | NCT03103594 | Aug 2015 → Aug 2016 | urinary bladder disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT05324839 | Feb → Mar 2014 | salivary substance, Clostridium botulinum type | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01520441 | Mar 2011 → Mar 2014 | benign prostatic hyperplasia, prostate cancer | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 0 | NCT00565201 | Oct 2007 → Dec 2009 | stroke disorder | Emory University | Completed | No outcome recorded |
| Phase 137 trials | ||||||
| Phase 1 | NCT07645456 | Oct 2025 → Apr 2026 | benign prostatic hyperplasia | Benha University | Completed | No outcome recorded |
| Phase 1 | NCT06928246 | Jul 2025 → Dec 2026 expected | atopic eczema | Daniel Kaplan | Recruiting | No outcome recorded |
| Phase 1 | NCT06778421 | Mar → Sep 2025 | — | Center for Advanced Facial Plastic Surgery | Completed | No outcome recorded |
| Phase 1 | NCT06834789 | Feb → Nov 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06788158 | Sep 2024 → Jan 2025 overdue | plantar fasciitis | Mexican Social Security Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05923996 | Feb → Jun 2024 | skin disorder | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04580238 | Dec 2023 → Jan 2025 | carotid artery dissection, cerebral sinovenous thrombosis, hemorrhagic stroke, migraine disorder +2 | University of Alberta | Withdrawn | No outcome recorded |
| Phase 1 | NCT05766683 | Mar → Jun 2023 overdue | — | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05784363 | Oct 2022 → Jun 2024 | — | Merz North America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05585398 | Oct 2022 → Feb 2023 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04925206 | Aug 2021 → Jan 2024 | beta thalassemia | EdiGene (GuangZhou) Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04970407 | Jul 2021 → Mar 2022 | — | Ipsen | Completed | No outcome recorded |
| Phase 1 | NCT04944953 | Jun → Sep 2021 | — | Hugel | Completed | No outcome recorded |
| Phase 1 | NCT04917731 | Jun 2021 → Jun 2023 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04631588 | Nov 2020 → Nov 2021 | — | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT04171258 | May 2020 → Apr 2021 | cervical dystonia | Hugel | Completed | No outcome recorded |
| Phase 1 | NCT04186442 | May 2020 → Apr 2021 | overactive bladder | Hugel | Completed | No outcome recorded |
| Phase 1 | NCT03236012 | Jan 2019 → Jan 2022 | isolated hyperchlorhidrosis | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT03069911 | Nov 2018 → May 2019 | Parkinson disease, depressive disorder | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1 | NCT03547141 | Apr → Aug 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03647982 | Mar → Oct 2018 | anhidrosis, isolated hyperchlorhidrosis | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03317717 | Oct 2017 → Jan 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT02008136 | Mar 2016 → Aug 2018 | — | VA Connecticut Healthcare System | Unknown | No outcome recorded |
| Phase 1 | NCT02577185 | Nov 2015 → Jul 2016 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02584686 | Oct 2015 → May 2016 | vasculogenic impotence | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT02782702 | Sep 2015 → Nov 2017 | Darier disease, Hailey-Hailey disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 1 | NCT02202070 | Jan → Dec 2015 | bruxism, temporomandibular joint dysfunction syndrome | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03203174 | Jan 2015 → Aug 2016 | — | University of California, Davis | Completed | No outcome recorded |
| Phase 1 | NCT02403219 | May 2013 → Feb 2014 | dry eye syndrome | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 1 | NCT01832194 | Mar 2013 → Apr 2014 | scrotal disorder | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 1 | NCT01352546 | Aug 2010 → Dec 2012 | vaginismus | Plastic Surgery Professional Association | Completed | No outcome recorded |
| Phase 1 | NCT00816517 | Jan 2009 → Jun 2015 | psoriasis | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT00515944 | Aug 2007 → Feb 2008 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00280280 | Feb 2006 → Feb 2009 | — | Vanderbilt University | Terminated | No outcome recorded |
| Phase 1 | NCT00529386 | Jan 2006 → Sep 2009 | chronic pain syndrome, chronic prostatitis | Queen's University | Terminated | No outcome recorded |
| Phase 1 | NCT00279903 | Nov 2005 → Aug 2008 | osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00175604 | Aug 2004 → Feb 2008 | — | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 1/228 trials | ||||||
| Phase 1/2 | NCT06230146 | May 2024 → Jan 2026 | keloid | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05158166 | Oct 2023 → Mar 2025 | spasmodic dystonia, voice disorders | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT05512039 | May 2023 → Sep 2026 expected | overactive bladder | Dartmouth-Hitchcock Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03991299 | Apr 2021 → Feb 2022 | obesity disorder, type 2 diabetes mellitus | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04752774 | Apr 2021 → Mar 2029 expected | — | Ipsen | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05127018 | Nov 2019 → Aug 2020 | — | Peking University | Completed | No outcome recorded |
| Phase 1/2 | NCT04281095 | Nov 2019 → Apr 2020 | — | ATGC Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03922139 | Oct 2019 → Dec 2021 | compartment syndrome | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1/2 | NCT03066635 | Apr 2017 → Sep 2019 | cluster headache syndrome | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT02674269 | Oct 2016 | overactive bladder | UroGen Pharma Ltd. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02662972 | May 2016 → Nov 2018 | headache disorder, trigeminal neuralgia | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT02639052 | Feb → Jul 2016 | — | Temple University | Completed | No outcome recorded |
| Phase 1/2 | NCT02074150 | Jan → Jun 2016 | focal dystonia, spastic monoplegia | li nguyen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02074293 | Jan → Jun 2016 | cervical dystonia | li nguyen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02074163 | Jan → Jun 2016 | hemicrania continua | ASIS Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02247193 | Dec 2015 → Jan 2020 | cleft lip, cleft palate | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT02498769 | Sep 2015 → Sep 2017 | atrial fibrillation | Joseph Mathew, M.D. | Completed | No outcome recorded |
| Phase 1/2 | NCT02259075 | Feb 2015 → Mar 2016 | migraine disorder | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT01553201 | Jul 2014 → Jul 2018 | chronic pain syndrome, endometriosis, levator syndrome | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1/2 | NCT02019017 | Oct 2013 → Feb 2014 | cluster headache syndrome | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT01921270 | Aug 2013 → Feb 2017 | oromandibular dystonia | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT01518257 | Jan 2012 → Jan 2013 | osteoarthritis | Allergan | Completed | No outcome recorded |
| Phase 1/2 | NCT00894517 | Aug 2009 → Jun 2012 | benign prostatic hyperplasia | Allergan | Completed | No outcome recorded |
| Phase 1/2 | NCT00770406 | Jan 2009 → Jun 2010 | overactive bladder | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00732680 | Dec 2008 → Nov 2009 | empty nose syndrome | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1/2 | NCT00479154 | May 2007 → Apr 2008 | restless legs syndrome | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1/2 | NCT00583219 | Mar 2006 → May 2008 | overactive bladder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00178945 | Mar 2004 → Mar 2006 | cervical dystonia, myofascial pain syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase 2158 trials | ||||||
| Phase 2 | NCT07489430 | Jul 2026 → Jun 2028 expected | benign essential blepharospasm | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07553065 | Jul 2026 → Sep 2027 expected | overactive bladder | Vensica Therapeutics Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07537855 | Jun 2026 → Jun 2028 expected | erectile dysfunction | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07399782 | Apr → Sep 2026 expected | obstructive sleep apnea syndrome | Hospital Felicio Rocho | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07486830 | Feb → Dec 2026 expected | vulvodynia | Center for Vulvovaginal Disorders | Recruiting | No outcome recorded |
| Phase 2 | NCT07399860 | Feb 2026 → Jan 2027 expected | hemorrhoid | Lomonosov Moscow State University Medical Research and Educational Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07335367 | Jan → Aug 2026 overdue | androgenetic alopecia | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06530524 | Oct 2024 → Oct 2026 expected | head and neck cancer | Sir Mortimer B. Davis - Jewish General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06293300 | Sep 2024 → Sep 2026 expected | traumatic brain injury | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT05606757 | May 2024 → Apr 2025 | abdominal wall malformation | AbbVie | Withdrawn | No outcome recorded |
| Show all 158 trials opens the full record — a long page | ||||||
| Phase 2/324 trials | ||||||
| Phase 2/3 | NCT06902805 | Dec 2025 → May 2027 expected | osteoarthritis, hand | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06755099 | Jan 2025 → Aug 2026 overdue | sexual disorder | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06721520 | Dec 2024 → Dec 2027 expected | achalasia, dyskinesia of esophagus, esophageal cancer, functional gastric disease | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06583590 | Aug 2024 → Aug 2025 overdue | erectile dysfunction | Aswan University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06851598 | Jul 2024 → Feb 2025 overdue | premature ejaculation | Abdallah Mohamed Abdallah Mohamed Elgendy | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04695600 | Aug 2023 → Aug 2027 expected | disorder of pharynx, dysphagia lusoria, retrograde cricopharyngeus dysfunction | All India Institute of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05878951 | Jul 2023 → Sep 2026 expected | overactive bladder | Northwestern University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05367271 | Aug 2022 → Sep 2024 | plantar fasciitis | Western Institute for Veterans Research | Completed | No outcome recorded |
| Phase 2/3 | NCT05651256 | Mar 2021 | temporomandibular joint disorder | University of Salamanca | Completed | No outcome recorded |
| Phase 2/3 | NCT04277247 | Jan 2021 → Dec 2022 | Parkinson disease, dystonic disorder | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT04756882 | Nov 2020 → May 2021 | reactive cutaneous fibrous lesion | Alexandria University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04274608 | Jan 2020 → Jul 2021 | obesity disorder | Tan Tock Seng Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03187626 | Nov 2018 → Feb 2021 | osteoarthritis, hand | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT03102762 | Jan 2017 → Jan 2019 | erectile dysfunction, sexual disorder | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT02886988 | Oct 2016 → Dec 2017 | — | Xijing Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02882893 | Aug 2016 → Jan 2017 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 2/3 | NCT03894748 | Dec 2011 → Aug 2012 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 2/3 | NCT01489904 | Nov 2011 | cerebral palsy | Hospital Vall d'Hebron | Unknown | No outcome recorded |
| Phase 2/3 | NCT00997815 | Dec 2009 → Dec 2010 | alopecia totalis, alopecia universalis | Siriraj Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02428881 | Nov 2009 → Jul 2012 | Fowler syndrome | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT01566292 | Sep 2009 → Sep 2010 | benign prostatic hyperplasia | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 2/3 | NCT00479596 | Jan → May 2007 | overactive bladder | Urological Sciences Research Foundation | Unknown | No outcome recorded |
| Phase 2/3 | NCT00447876 | Jul 2005 → Jan 2009 | plantar fasciitis | Ipsen | Completed | No outcome recorded |
| Phase 2/3 | NCT00370734 | May 2005 → Feb 2007 | eye disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3185 trials | ||||||
| Phase 3 | NCT05698979 | Jan 2027 → Feb 2028 expected | Raynaud disease, thromboangiitis obliterans | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07470164 | Jan 2027 → Jan 2030 expected | esotropia | Jaeb Center for Health Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06995287 | Feb 2026 → Jun 2028 expected | chronic pain syndrome, primary dysmenorrhea | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07210463 | Oct 2025 → Jan 2027 expected | — | Merz Aesthetics GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT07122193 | Aug 2025 → Oct 2026 expected | — | Merz North America, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07018700 | Aug 2025 → Mar 2027 expected | migraine disorder | Merz Therapeutics GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT07018713 | Aug 2025 → Oct 2027 expected | migraine disorder | Merz Therapeutics GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT07013240 | Jul 2025 → Feb 2027 expected | — | University Hospital, Bordeaux | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06794866 | Jan 2025 → Apr 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT06499324 | Jan 2025 → Aug 2028 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Show all 185 trials opens the full record — a long page | ||||||
| Phase 4124 trials | ||||||
| Phase 4 | NCT07295288 | Jul 2026 → Jun 2027 expected | cranial nerve neuropathy | Vanderbilt University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07646886 | Jul 2026 → Jun 2027 expected | — | Peking University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05393921 | Jun 2026 → Jul 2027 | benign prostatic hyperplasia, overactive bladder | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT07220382 | Nov 2025 → Dec 2027 expected | abdominal wall malformation, compartment syndrome | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07082972 | Sep 2025 → Sep 2026 expected | myofascial pain syndrome | Istanbul University | Recruiting | No outcome recorded |
| Phase 4 | NCT06195241 | Feb 2025 → Mar 2027 expected | benign essential blepharospasm, facial spasm | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06783621 | Jan 2025 → Mar 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT06237465 | Jan → Jun 2025 | hidradenitis suppurativa | Yale University | Withdrawn | No outcome recorded |
| Phase 4 | NCT06556030 | Jan 2025 → Jun 2026 overdue | salivary substance, Clostridium botulinum type | Instituto de Investigación Hospital Universitario La Paz | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06356025 | Sep 2024 → Dec 2025 overdue | retrograde cricopharyngeus dysfunction | AZ Delta | Active not recruiting | No outcome recorded |
| Show all 124 trials opens the full record — a long page | ||||||
| Phase not applicable101 trials | ||||||
| — | NCT07666347 | Jun → Dec 2026 expected | osteoarthritis, knee | Tanta University | Recruiting | No outcome recorded |
| — | NCT07665528 | Jun → Sep 2026 expected | ulcer of anus and rectum | Islamabad Medical and Dental College | Recruiting | No outcome recorded |
| — | NCT07626983 | May → Dec 2026 expected | chronic pain syndrome, nervous system injury, neuroma | Ukrainian Society of Regional Anesthesia and Pain Therapy | Not yet recruiting | No outcome recorded |
| — | NCT07624877 | May 2026 overdue | chronic pain syndrome, neuroma | Ukrainian Society of Regional Anesthesia and Pain Therapy | Not yet recruiting | No outcome recorded |
| — | NCT07535723 | Apr → Oct 2026 expected | migraine disorder | Beni-Suef University | Not yet recruiting | No outcome recorded |
| — | NCT07568314 | Mar → Jun 2026 overdue | ulcer of anus and rectum | Islamabad Medical and Dental College | Recruiting | No outcome recorded |
| — | NCT07431944 | Feb 2026 overdue | — | Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans) | Not yet recruiting | No outcome recorded |
| — | NCT07673471 | Feb → May 2026 | bruxism, odontoclasia | Biruni University | Completed | No outcome recorded |
| — | NCT07452510 | Jan → Apr 2026 | bruxism, masticatory muscles, hypertrophy of, parasomnia, sleep bruxism type, temporomandibular joint disorder | Recep Tayyip Erdogan University | Completed | No outcome recorded |
| — | NCT07473635 | Jan → Jul 2026 overdue | complex regional pain syndrome type 1, complex regional pain syndrome type 2 | Bo Biering-Soerensen | Recruiting | No outcome recorded |
| — | NCT07236632 | Dec 2025 → Dec 2026 expected | premature ejaculation | Benha University | Not yet recruiting | No outcome recorded |
| — | NCT07070817 | Dec 2025 → Dec 2026 | — | houyajing | Withdrawn | No outcome recorded |
| — | NCT07270042 | Dec 2025 → Sep 2026 expected | masticatory muscles, hypertrophy of | Latakia University | Not yet recruiting | No outcome recorded |
| — | NCT07561580 | Nov 2025 → Jul 2026 overdue | isolated hyperchlorhidrosis | Latakia University | Recruiting | No outcome recorded |
| — | NCT07160699 | Oct 2025 → Oct 2026 expected | — | Technical University of Bern | Not yet recruiting | No outcome recorded |
| — | NCT07545200 | Sep 2025 → Feb 2026 | bruxism, masticatory muscles, hypertrophy of, myofascial pain syndrome | Kahramanmaras Sutcu Imam University | Completed | No outcome recorded |
| — | NCT06974617 | May → Oct 2025 overdue | migraine disorder | Cairo University | Recruiting | No outcome recorded |
| — | NCT07137234 | Mar 2025 → May 2026 overdue | cleft lip | Mansoura University | Recruiting | No outcome recorded |
| — | NCT05910983 | Jan → Nov 2025 | benign prostatic hyperplasia, bladder neck obstruction, overactive bladder | Menoufia University | Unknown | No outcome recorded |
| — | NCT06553950 | Aug 2024 → Feb 2025 overdue | temporomandibular joint disorder | Cairo University | Recruiting | No outcome recorded |
| — | NCT07526870 | Jul → Nov 2024 | — | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| — | NCT06470581 | Jul 2024 → Apr 2026 overdue | complex regional pain syndrome | Seoul National University | Not yet recruiting | No outcome recorded |
| — | NCT06840730 | Jun 2024 → Jan 2025 | temporomandibular joint dysfunction syndrome | Hacettepe University | Completed | No outcome recorded |
| — | NCT07076355 | May → Dec 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07549113 | Apr 2024 → May 2027 expected | — | State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital | Recruiting | No outcome recorded |
| — | NCT06328556 | Mar → Dec 2024 | achalasia | Copka Sonpashan | Unknown | No outcome recorded |
| — | NCT07385742 | Jan 2024 → Mar 2025 | temporomandibular joint disorder | Suez Canal University | Completed | No outcome recorded |
| — | NCT06218316 | Oct 2023 → Jan 2024 | spastic diplegia | MTI University | Completed | No outcome recorded |
| — | NCT05604729 | Sep 2023 → Dec 2024 | bruxism, tooth erosion, non-bacterial | Region Västerbotten | Unknown | No outcome recorded |
| — | NCT06345677 | Jun 2023 → Feb 2024 | overactive bladder | Vensica Therapeutics Ltd. | Completed | No outcome recorded |
| — | NCT04220931 | Mar 2023 → Dec 2026 expected | pancreas disorder | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| — | NCT05752123 | Feb 2023 → Jan 2024 | beta thalassemia | EdiGene (GuangZhou) Inc. | Terminated | No outcome recorded |
| — | NCT04390971 | Feb → Mar 2023 | beta thalassemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| — | NCT06179082 | Feb → Oct 2023 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT05863286 | Dec 2022 → Dec 2023 | temporomandibular joint disorder | Cairo University | Unknown | No outcome recorded |
| — | NCT06196606 | Nov 2022 → Dec 2024 | brain stem infarction, esophageal disorder | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| — | NCT06213662 | Nov 2022 → Jul 2024 | achalasia | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| — | NCT05382832 | Aug 2022 | migraine disorder | EPC Education s.r.o. | Unknown | No outcome recorded |
| — | NCT06122545 | May 2022 → May 2024 | migraine disorder | Tanta University | Unknown | No outcome recorded |
| — | NCT06282679 | Apr 2022 → Mar 2024 | rosacea, salivary substance, Clostridium botulinum type | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT06225024 | Mar 2022 → Jun 2023 | stroke disorder | Kayseri City Hospital | Completed | No outcome recorded |
| — | NCT05911594 | Feb 2022 → Feb 2023 | — | Benha University | Completed | No outcome recorded |
| — | NCT05194488 | Jan → May 2022 | temporomandibular joint dysfunction syndrome | Nourhan M.Aly | Completed | No outcome recorded |
| — | NCT05138835 | Nov 2021 → Nov 2022 | — | Andreas Nikolis | Completed | No outcome recorded |
| — | NCT07426640 | Nov 2021 → Nov 2024 | premature ejaculation | Al Mouwasat Hospital | Completed | No outcome recorded |
| — | NCT05517538 | Aug → Dec 2021 | — | Mohamed Hayder Oleish Salih | Completed | No outcome recorded |
| — | NCT05620316 | Mar → Sep 2021 | parasomnia, sleep bruxism type | Damascus University | Completed | No outcome recorded |
| — | NCT04383912 | Nov 2020 → Jul 2024 | Tented eyebrows | Nova Scotia Health Authority | Unknown | No outcome recorded |
| — | NCT04940143 | Aug 2020 → Jul 2021 | cerebral palsy spastic hemiplegic | Marmara University | Unknown | No outcome recorded |
| — | NCT04270214 | Jun 2020 → Oct 2022 | cervical dystonia | Western University, Canada | Unknown | No outcome recorded |
| — | NCT05309564 | Mar 2020 → Jan 2022 | salivary substance, Clostridium botulinum type | Region Västerbotten | Completed | No outcome recorded |
| — | NCT04290169 | Feb 2020 → Mar 2022 | spastic cerebral palsy | Sunnaas Rehabilitation Hospital | Unknown | No outcome recorded |
| — | NCT03891680 | Oct 2019 → Mar 2020 | osteoarthritis, knee | Assiut University | Completed | No outcome recorded |
| — | NCT04366869 | Jul 2019 → Jul 2020 | bruxism | October University for Modern Sciences and Arts | Completed | No outcome recorded |
| — | NCT03284047 | Apr 2019 | gingival disorder | Northwestern University | Withdrawn | No outcome recorded |
| — | NCT04940104 | Jan → Jun 2019 | bruxism | British University In Egypt | Completed | No outcome recorded |
| — | NCT04544280 | Sep 2018 → Dec 2021 | stroke disorder | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT03891121 | Apr 2018 → Feb 2019 | myofascial pain syndrome, temporomandibular joint disorder | Ankara University | Completed | No outcome recorded |
| — | NCT03484754 | Apr 2018 → Jul 2021 | major depressive disorder | Centre Hospitalier Esquirol | Unknown | No outcome recorded |
| — | NCT03747900 | Oct 2017 → Mar 2018 | — | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT03306940 | Oct 2017 → Jul 2018 | facial spasm | Tongji University | Unknown | No outcome recorded |
| — | NCT03131791 | Apr → Jul 2017 | diplegia of upper limb | Mackay Memorial Hospital | Completed | No outcome recorded |
| — | NCT03704155 | Jan 2017 → May 2018 | spastic cerebral palsy | University of Nove de Julho | Completed | No outcome recorded |
| — | NCT02917967 | Nov 2016 → Sep 2018 | cerebral palsy | Yonsei University | Completed | No outcome recorded |
| — | NCT02909907 | Aug 2016 → Feb 2018 | essential tremor | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT02351544 | Sep 2015 → Jun 2022 | migraine disorder | Ohio State University | Completed | No outcome recorded |
| — | NCT02369068 | Aug 2015 → Mar 2018 | pelvis syndrome | Jamie Bartley, DO | Completed | No outcome recorded |
| — | NCT02444351 | Jun 2015 → Jun 2016 | spinal stenosis | Yonsei University | Completed | No outcome recorded |
| — | NCT02187679 | Jan 2014 → Jun 2017 | Tourette syndrome, chronic tic disorder | Detroit Clinical Research Center | Unknown | No outcome recorded |
| — | NCT02168634 | Nov 2013 → Dec 2015 | reactive cutaneous fibrous lesion, salivary substance, Clostridium botulinum type | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| — | NCT01859507 | Jan 2013 → Mar 2014 | vaginismus | Abdel-Maguid Ramzy | Completed | No outcome recorded |
| — | NCT01635504 | Oct 2012 → Jan 2015 | AIDS dysmorphic syndrome | University of British Columbia | Completed | No outcome recorded |
| — | NCT01829087 | Aug 2012 → Aug 2014 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT01483209 | Mar 2012 → Apr 2014 | ischemic disease | Duke University | Terminated | No outcome recorded |
| — | NCT01803464 | Mar 2012 → Feb 2015 | cerebral palsy | University of Delaware | Completed | No outcome recorded |
| — | NCT01274611 | Dec 2010 → Dec 2011 | isolated hyperchlorhidrosis | Northwestern University | Completed | No outcome recorded |
| — | NCT01225341 | Aug 2010 → May 2012 | herpes labialis | DeNova Research | Terminated | No outcome recorded |
| — | NCT01760577 | May 2010 → May 2012 | osteoarthritis | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT00999869 | Nov 2009 → Dec 2012 | alopecia areata | Siriraj Hospital | Unknown | No outcome recorded |
| — | NCT06899438 | Aug 2009 → Jan 2010 | myofascial pain syndrome | Bursa City Hospital | Completed | No outcome recorded |
| — | NCT00822523 | Jan → Mar 2009 | salivary substance, Clostridium botulinum type | Loma Linda University | Completed | No outcome recorded |
| — | NCT00822926 | Jan 2009 → Dec 2013 | — | Stanford University | Terminated | No outcome recorded |
| — | NCT00900666 | Jan 2009 → Jun 2011 | brain injury | Mary Free Bed Rehabilitation Hospital | Terminated | No outcome recorded |
| — | NCT00725322 | Dec 2007 → Mar 2013 | — | Stanford University | Completed | No outcome recorded |
| — | NCT00408798 | Oct 2007 → Oct 2009 | alopecia areata | University of British Columbia | Completed | No outcome recorded |
| — | NCT00435682 | Mar 2007 → Jan 2008 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT00395616 | Nov 2006 → ? | epicondylitis, salivary substance, Clostridium botulinum type | E-DA Hospital | Unknown | No outcome recorded |
| — | NCT00336349 | Jun 2006 → Dec 2007 | diabetes mellitus, neuropathy, painful | Taipei Medical University Hospital | Completed | No outcome recorded |
| — | NCT01590693 | Nov 2005 → Jan 2012 | — | Karolinska Institutet | Completed | No outcome recorded |
| — | NCT00345332 | Oct 2005 → May 2011 | — | University of Rochester | Completed | No outcome recorded |
| — | NCT00152334 | Sep 2005 → Mar 2016 | clubfoot | University of British Columbia | Completed | No outcome recorded |
| — | NCT00152347 | Sep 2005 → Sep 2015 | clubfoot | University of British Columbia | Completed | No outcome recorded |
| — | NCT00250952 | Feb → Jun 2005 | skin atrophy | Carruthers Dermatology Centre | Completed | No outcome recorded |
| — | NCT00850421 | Apr 2004 → Apr 2010 | migraine disorder | HealthPartners Institute | Terminated | No outcome recorded |
| — | NCT01129583 | Nov 2003 → Sep 2009 | — | Columbia University | Completed | No outcome recorded |
| — | NCT00661089 | Sep 2003 → Mar 2009 | — | Shirley Ryan AbilityLab | Completed | No outcome recorded |
| — | NCT00173745 | Jun 2003 → Sep 2005 | cerebral palsy | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT00474032 | Mar 2003 → Mar 2023 | clubfoot | University of British Columbia | Unknown | No outcome recorded |
| — | NCT00282958 | Feb 2003 → Jul 2006 | — | Palo Alto Veterans Institute for Research | Completed | No outcome recorded |
| — | NCT00004480 | Jul 1999 → ? | isolated hyperchlorhidrosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT00004416 | Jan 1997 → Mar 2002 | achalasia | University of Texas | Completed | No outcome recorded |
Also used as a comparator or background therapy in 278 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06811142 Comparator | Jan 2025 → Feb 2027 expected | stroke disorder | Mexican Social Security Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06793683 Comparator | Jul 2024 → Apr 2028 expected | spinal cord injury | University of Washington | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06013644 Comparator | Jun 2023 → Feb 2024 | myofascial pain syndrome | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT05807412 Comparator | May 2023 → Feb 2024 | — | Lupo Center for Aesthetic and General Dermatology | Completed | No outcome recorded |
| Phase 0 | NCT05305768 Comparator | May 2022 → Feb 2023 | — | Clinical Testing of Beverly Hills | Unknown | No outcome recorded |
| Phase 0 | NCT05083286 Comparator | Oct 2021 → Aug 2022 | — | Clinical Testing of Beverly Hills | Unknown | No outcome recorded |
| Phase 0 | NCT03616262 Comparator | Jul 2016 → Dec 2019 | complex regional pain syndrome | VA Connecticut Healthcare System | Unknown | No outcome recorded |
| Phase 0 | NCT02524236 Comparator | Aug 2015 → Nov 2016 | benign prostatic hyperplasia | Beni-Suef University | Completed | No outcome recorded |
| Phase 0 | NCT02460107 Comparator | May 2015 → Nov 2016 | neuralgia | Catholic University of Korea Saint Paul's Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT02019004 Comparator | Nov 2013 → Dec 2027 expected | — | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 119 trials | ||||||
| Phase 1 | NCT06604832 Comparator | Sep 2024 → Aug 2025 | — | Kalpna Kay Durairaj, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT07361900 Comparator | Mar 2024 → Jul 2025 | parasomnia, sleep bruxism type | Delta University for Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT05956509 Comparator | Jan → Jun 2024 | — | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT06212960 Comparator | Nov 2023 → Feb 2024 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT07292025 Comparator | Jun 2023 → Apr 2024 | diplegia of upper limb | Jetema Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05496335 Background | Aug 2022 → May 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05428930 Comparator | Jun → Oct 2022 | — | CKD Bio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05382767 Comparator | Jun → Dec 2022 | diplegia of upper limb | CKD Bio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05292638 Comparator | Feb → Jun 2022 | — | CKD Bio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03833063 Comparator | May → Dec 2019 | major depressive disorder | Helse Stavanger HF | Withdrawn | No outcome recorded |
| Phase 1 | NCT03371342 Comparator | Dec 2017 → May 2018 | overactive bladder | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT05164003 Comparator | Jul → Sep 2017 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT02400619 Comparator | Sep 2014 → Jun 2015 | cerebral palsy | Xavi Vidal Novellas | Completed | No outcome recorded |
| Phase 1 | NCT02173405 Comparator | Aug 2014 → Sep 2015 | myofascial pain syndrome | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03796351 Comparator | Sep 2012 → Jan 2013 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT01495962 Comparator | Nov 2011 → Aug 2014 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01405482 Comparator | Aug 2011 → Dec 2012 | thoracic outlet syndrome | University of British Columbia | Unknown | No outcome recorded |
| Phase 1 | NCT00976443 Comparator | Sep 2009 → Sep 2011 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00549341 Comparator | May 2006 → Sep 2008 | spasmodic dystonia | Mentor Worldwide, LLC | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT06824324 Comparator | Mar → Nov 2024 | myofascial pain syndrome | Yassir R. Al-khannaq | Completed | No outcome recorded |
| Phase 1/2 | NCT06199336 Comparator | Jan → Sep 2024 | — | JHM BioPharma (Tonghua) Co. , Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05892770 Background | Aug 2023 → Dec 2025 overdue | spasmodic dystonia | University of Florida | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04585620 Comparator | Sep 2022 → Dec 2023 | chronic pain syndrome, neuropathy, painful | Allan Vestergaard Danielsen, MD | Unknown | No outcome recorded |
| Phase 1/2 | NCT05743634 Comparator | Mar 2022 → Feb 2023 | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04886167 Comparator | May 2021 → Nov 2022 | — | Clinical Testing of Beverly Hills | Unknown | No outcome recorded |
| Phase 1/2 | NCT04821089 Comparator | Apr 2021 → Aug 2026 overdue | — | Ipsen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04996810 Comparator | Dec 2020 → Apr 2021 | — | Protox Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03970876 Comparator | Apr → Sep 2019 | — | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT02961673 Comparator | Sep 2016 → Feb 2017 | — | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 251 trials | ||||||
| Phase 2 | NCT06465056 Comparator | Jan 2024 → Jan 2025 | ptosis | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT06003049 Comparator | Oct 2023 → Apr 2024 | chronic obstructive pulmonary disease | RMW Testing | Completed | No outcome recorded |
| Phase 2 | NCT05720065 Comparator | Sep 2023 → Jun 2025 overdue | temporomandibular joint disorder | Karolinska Institutet | Recruiting | No outcome recorded |
| Phase 2 | NCT05623111 Comparator | Aug 2023 → May 2027 expected | diabetic neuropathy | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 2 | NCT06034288 Comparator | May 2023 → Jun 2024 | overactive bladder | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05673655 Comparator | Dec 2022 → Feb 2023 | myofascial pain syndrome | Fayoum University | Unknown | No outcome recorded |
| Phase 2 | NCT06460194 Comparator | Nov 2022 → Jul 2023 | neuropathy, painful, perceptual disorders, vascular insufficiency disorder | University Hospital of North Norway | Withdrawn | No outcome recorded |
| Phase 2 | NCT05320393 Comparator | Mar 2022 → May 2023 | — | Evolus, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05298449 Comparator | Mar → Nov 2022 | — | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04922983 Comparator | Jul 2021 → Jul 2025 | adolescent idiopathic scoliosis | Manhattan Physical Medicine and Rehabilitation, LLP | Unknown | No outcome recorded |
| Phase 2 | NCT04401176 Comparator | Sep 2020 → Jun 2023 | interstitial cystitis | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04426123 Comparator | Jul → Dec 2020 | myofascial pain syndrome | Region Örebro County | Unknown | No outcome recorded |
| Phase 2 | NCT04502264 Background | Jan 2020 → Feb 2024 | stroke disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04080882 Comparator | Sep → Dec 2019 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT03903653 Comparator | Sep → Nov 2019 | — | Hamilton Health Sciences Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT02728778 Comparator | Sep 2016 → Apr 2019 | borderline personality disorder | Hannover Medical School | Completed | No outcome recorded |
| Phase 2 | NCT03355963 Comparator | Jul 2016 → Jan 2019 | erectile dysfunction, salivary substance, Clostridium botulinum type | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT02736890 Comparator | Mar 2016 → Jul 2018 | neuropathy, painful, spinal cord injury | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 2 | NCT02160288 Comparator | Feb 2016 → Jun 2019 | outlet dysfunction constipation | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02434549 Comparator | Aug 2015 → Jan 2018 | spastic cerebral palsy | Kristina Tedroff | Terminated | No outcome recorded |
| Phase 2 | NCT01374191 Comparator | Jan 2015 → May 2017 | neuroma | Southern Illinois University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02303002 Comparator | Dec 2014 → Dec 2015 | — | Revance Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03119948 Comparator | Dec 2014 → Nov 2017 | palsy, traumatic brain injury | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT02070302 Comparator | Oct 2014 → Feb 2016 | carpal tunnel syndrome | Benjamin Sucher | Completed | No outcome recorded |
| Phase 2 | NCT03238898 Comparator | Sep 2014 → May 2017 | muscle cramps, familial, type 2 diabetes mellitus | Presidio Ospedaliero Garibaldi-Centro | Completed | No outcome recorded |
| Phase 2 | NCT02188277 Comparator | Jul 2014 → Dec 2016 | cerebral palsy, clubfoot | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02088632 Comparator | Mar 2014 → Jun 2015 | trigeminal neuralgia | Thomas Jefferson University | Terminated | No outcome recorded |
| Phase 2 | NCT02107261 Comparator | Mar 2014 → Jan 2020 | focal, segmental or multifocal dystonia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02010775 Comparator | Jan 2014 → Mar 2017 | masticatory muscles, hypertrophy of | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01911377 Comparator | Oct 2013 → May 2015 | allesthesia, neuropathy, painful | University of Manitoba | Terminated | No outcome recorded |
| Phase 2 | NCT02907268 Comparator | Sep 2013 → Jan 2014 | — | ICLS Dermatology & Plastic Surgery | Completed | No outcome recorded |
| Phase 2 | NCT01930604 Comparator | Sep 2013 → Oct 2019 | isolated hyperchlorhidrosis | Carl Swartling | Unknown | No outcome recorded |
| Phase 2 | NCT02002962 Comparator | Jun 2013 → Jun 2015 | atrial flutter | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02221648 Comparator | Dec 2012 → Sep 2015 | — | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT01931878 Comparator | Sep 2012 → Aug 2015 | restless legs syndrome | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02419313 Comparator | Aug 2012 → Sep 2015 | Parkinson disease, movement disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01588574 Comparator | Aug 2012 → Oct 2013 | cervical dystonia | Medy-Tox | Completed | No outcome recorded |
| Phase 2 | NCT01589263 Comparator | Jun 2012 → Sep 2019 | benign prostatic hyperplasia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01473277 Comparator | Jan → Jun 2012 | arthropathy, hemiplegia, stroke disorder | The Foundation Institute San Raffaele G. Giglio of Cefalù | Unknown | No outcome recorded |
| Phase 2 | NCT02662530 Comparator | Jan 2012 → Dec 2020 | cervical dystonia | Western University, Canada | Unknown | No outcome recorded |
| Phase 2 | NCT01309802 Comparator | May 2011 → May 2016 | Raynaud disease | Southern Illinois University | Completed | No outcome recorded |
| Phase 2 | NCT01333397 Comparator | Mar → Sep 2011 | — | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT01282541 Comparator | Feb 2011 → Sep 2012 | excessive tearing | Merbs, Shannath, M.D., Ph.D. | Completed | No outcome recorded |
| Phase 2 | NCT02212119 Comparator | Dec 2010 → Feb 2013 | dementia, paroxysmal dystonia | Assistive Technology Clinic, Canada | Completed | No outcome recorded |
| Phase 2 | NCT00773591 Comparator | Mar → Oct 2010 | sleep apnea syndrome | Merz Pharmaceuticals GmbH | Withdrawn | No outcome recorded |
| Phase 2 | NCT01064518 Comparator | Jan → Jul 2010 | eyelid disorder | Revance Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00968942 Comparator | Aug → Oct 2009 | eyelid disorder | Revance Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00968825 Comparator | Jul → Oct 2009 | eyelid disorder | Revance Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00711087 Comparator | Jul 2007 → Feb 2010 | spinal cord injury, urinary bladder disorder | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00444886 Comparator | May 2007 → Feb 2011 | thoracic outlet syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00451191 Comparator | Oct 2006 → Jun 2009 | benign prostatic hyperplasia | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT06676475 Comparator | Dec 2024 → Feb 2025 overdue | myofascial pain syndrome | Misr University for Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06783114 Comparator | Sep 2024 → Sep 2026 expected | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06296082 Comparator | Sep 2024 → Dec 2026 expected | stroke disorder | University of Antwerp | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06814535 Comparator | Jun 2024 → Mar 2025 overdue | myofascial pain syndrome | Cairo University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04172558 Comparator | Mar 2019 → Oct 2022 | erectile dysfunction | Benha University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05618470 Comparator | Jan 2018 → Aug 2024 | benign essential blepharospasm, blepharospasm-oromandibular dystonia syndrome, dry eye syndrome | China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT02947815 Comparator | Oct 2016 → Jan 2018 | benign essential blepharospasm | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 2/3 | NCT01262339 Comparator | Nov 2010 → Apr 2012 | hyperhidrosis palmaris ET plantaris | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 2/3 | NCT01350375 Comparator | Sep 2009 → Jan 2013 | headache disorder | The Research Center of Southern California | Completed | No outcome recorded |
| Phase 2/3 | NCT02425176 Comparator | Sep 2009 → Feb 2014 | — | University of Malaya | Completed | No outcome recorded |
| Phase 2/3 | NCT00660192 Comparator | Jan 2008 → Jul 2012 | migraine disorder | Yale University | Completed | No outcome recorded |
| Phase 363 trials | ||||||
| Phase 3 | NCT07013279 Comparator | Jul → Dec 2025 overdue | — | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07040813 Comparator | Jun 2025 → Jan 2029 expected | migraine disorder | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06941636 Comparator | May 2025 → Dec 2026 expected | temporomandibular joint disorder | Region Stockholm | Recruiting | No outcome recorded |
| Phase 3 | NCT06937944 Comparator | Apr → Dec 2025 overdue | — | JHM BioPharma (Tonghua) Co. , Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06729840 Comparator | Dec 2024 → Apr 2025 overdue | keloid formation | Sohag University | Recruiting | No outcome recorded |
| Phase 3 | NCT06585696 Comparator | Jun 2024 → Nov 2025 | — | Cutia Therapeutics (Wuxi) Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06946160 Comparator | May 2024 → Feb 2025 | — | Espad Pharmed | Completed | No outcome recorded |
| Phase 3 | NCT05801146 Comparator | Jan 2024 → Mar 2025 | — | Hugel | Unknown | No outcome recorded |
| Phase 3 | NCT06499688 Comparator | Dec 2023 → Mar 2024 | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06315790 Comparator | Nov 2023 → Oct 2025 | trigeminal neuralgia | Henrik Schytz | Unknown | No outcome recorded |
| Phase 3 | NCT06128616 Background | Nov 2023 → Jun 2024 | spastic cerebral palsy | Kocaeli University | Unknown | No outcome recorded |
| Phase 3 | NCT06047444 Comparator | Oct 2023 → May 2026 overdue | migraine disorder | Ipsen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06047457 Comparator | Sep 2023 → Jun 2026 overdue | migraine disorder | Ipsen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05804656 Comparator | Apr → Aug 2023 | — | CKD Bio Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05364580 Comparator | Mar → Jun 2023 | — | Protox Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05598723 Comparator | Feb 2023 → Feb 2026 overdue | migraine disorder | Naval Medical Center Camp Lejeune | Recruiting | No outcome recorded |
| Phase 3 | NCT05623410 Comparator | Oct 2022 → Feb 2023 | — | ATGC Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05463965 Comparator | Jul 2022 → Jan 2023 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT06840158 Comparator | Oct 2021 → May 2022 | cerebral palsy | Innopharm LLC | Completed | No outcome recorded |
| Phase 3 | NCT05059587 Comparator | Aug → Dec 2021 | — | Medytox Korea | Completed | No outcome recorded |
| Phase 3 | NCT07622004 Comparator | May 2021 → Jan 2022 | — | INIBIO Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05531968 Comparator | Feb → Aug 2021 | — | BMI Korea | Completed | No outcome recorded |
| Phase 3 | NCT06354127 Comparator | Aug → Nov 2020 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04830345 Comparator | Jun 2020 → Sep 2021 | — | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04171531 Comparator | Jun 2020 → Feb 2024 | female stress incontinence, overactive bladder | NICHD Pelvic Floor Disorders Network | Completed | No outcome recorded |
| Phase 3 | NCT04073303 Comparator | Aug 2019 → Nov 2022 | masticatory muscles, hypertrophy of | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03717987 Comparator | Jan → Sep 2019 | gingival disorder | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03837561 Comparator | Dec 2018 → Mar 2019 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT04081402 Comparator | Nov 2018 → Nov 2019 | — | Huons Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03758235 Comparator | Sep 2018 → Sep 2021 | overactive bladder | University Of Perugia | Unknown | No outcome recorded |
| Phase 3 | NCT03472261 Background | Mar 2018 → Mar 2020 | cerebral palsy | Kocaeli University | Completed | No outcome recorded |
| Phase 3 | NCT03977493 Comparator | Feb 2018 → Dec 2027 expected | focal hand dystonia | Alain Kaelin | Recruiting | No outcome recorded |
| Phase 3 | NCT03408236 Comparator | Jan → Dec 2018 | — | Hugel | Completed | No outcome recorded |
| Phase 3 | NCT03440671 Comparator | Nov 2017 → Oct 2018 | — | Huons Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03289702 Comparator | Nov 2017 → Jun 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03331913 Comparator | Nov 2017 → Feb 2019 | trigeminal neuralgia | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 3 | NCT03317574 Comparator | Aug → Dec 2017 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT05380154 Comparator | May 2017 → Jan 2018 | — | Hugel | Completed | No outcome recorded |
| Phase 3 | NCT03216473 Comparator | May 2016 → Mar 2017 | benign essential blepharospasm | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT02749591 Background | May 2016 → Nov 2017 | stroke disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02773641 Comparator | May 2016 → Jun 2019 | vulvodynia | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT03216408 Comparator | Mar → Nov 2016 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT02786407 Comparator | Mar 2016 → Nov 2018 | overactive bladder | Lanzhou Institute of Biological Products Co., Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT03302871 Background | Jan 2016 → Jan 2020 | cerebral palsy | Kocaeli University | Completed | No outcome recorded |
| Phase 3 | NCT02450526 Comparator | Apr 2015 → Jul 2016 | — | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT03306212 Background | Nov 2014 → Dec 2017 | cerebral palsy | Kocaeli University | Completed | No outcome recorded |
| Phase 3 | NCT02291380 Comparator | Sep 2014 → Dec 2019 | migraine disorder | Lanzhou Institute of Biological Products Co., Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT03905304 Comparator | Jan 2013 → Jul 2014 | cervical dystonia | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT01753310 Comparator | Jan 2013 → Oct 2014 | cervical dystonia | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT01776606 Comparator | Dec 2012 → May 2013 | skin atrophy | Revance Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01787344 Comparator | Mar 2012 → Jun 2014 | cerebral palsy | Hugel | Completed | No outcome recorded |
| Phase 3 | NCT01629875 Comparator | Mar → Aug 2012 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT01502956 Comparator | Feb 2012 → Jul 2016 | overactive bladder | NICHD Pelvic Floor Disorders Network | Completed | No outcome recorded |
| Phase 3 | NCT01180348 Comparator | Aug → Oct 2011 | — | Azidus Brasil | Completed | No outcome recorded |
| Phase 3 | NCT01261611 Comparator | Apr 2011 → May 2012 | cervical dystonia | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT01313767 Comparator | Mar 2011 → Jan 2012 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT01357798 Comparator | Dec 2010 → Apr 2011 | allesthesia, headache disorder | Federal University of Bahia | Completed | No outcome recorded |
| Phase 3 | NCT01220726 Comparator | Jun 2009 → Jun 2011 | overactive bladder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 3 | NCT00819065 Comparator | Mar 2009 → May 2010 | — | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT00777803 Comparator | Nov 2008 → Apr 2009 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00497913 Comparator | Aug 2007 → Mar 2008 | epicondylitis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00412035 Comparator | Jan 2007 → Dec 2012 | congenital deformities of limbs, congenital limb malformation | Shriners Hospitals for Children | Completed | No outcome recorded |
| Phase 3 | NCT00682760 Comparator | Oct 2005 → Feb 2006 | benign essential blepharospasm | Pacific Pharmaceuticals | Completed | No outcome recorded |
| Phase 473 trials | ||||||
| Phase 4 | NCT06448676 Comparator | Feb 2026 → Jan 2027 expected | — | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 4 | NCT06886750 Comparator | Mar 2025 → Mar 2027 expected | cervical dystonia | Western University, Canada | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07586072 Comparator | Aug 2024 → Aug 2025 | bruxism, myofascial pain syndrome, temporomandibular joint disorder | Recep Tayyip Erdogan University | Completed | No outcome recorded |
| Phase 4 | NCT06724250 Comparator | Aug 2023 → Aug 2024 | outlet dysfunction constipation | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT05806164 Comparator | Jun 2023 → Aug 2026 overdue | overactive bladder | Women and Infants Hospital of Rhode Island | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05887479 Comparator | May → Jul 2023 | cerebrovascular disorder, salivary substance, Clostridium botulinum type | Sisli Hamidiye Etfal Training and Research Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT06796855 Comparator | Feb 2023 → Feb 2024 | overactive bladder | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05724771 Background | Jan 2023 → Mar 2025 overdue | migraine disorder | Chicago Headache Center & Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05652036 Comparator | Jul 2022 → Apr 2023 | overactive bladder | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT06583343 Comparator | Jun 2022 → May 2023 | spastic diplegia | Gaziosmanpasa Research and Education Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07072806 Comparator | Jun → Aug 2022 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT05277337 Comparator | Feb → Oct 2022 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT05057117 Comparator | Sep 2021 → Oct 2022 | isolated hyperchlorhidrosis | Merete Haedersdal | Completed | No outcome recorded |
| Phase 4 | NCT04819360 Comparator | Jun 2021 → Mar 2022 | multiple sclerosis, urinary bladder disorder | Brigitte Schürch | Terminated | No outcome recorded |
| Phase 4 | NCT05296759 Comparator | Feb → Nov 2021 | diabetic neuropathy | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT04810429 Comparator | Jan → Dec 2021 | temporomandibular joint disorder | Instituto Portugues da Face | Completed | No outcome recorded |
| Phase 4 | NCT05840445 Comparator | Jun 2020 → Jan 2021 | — | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 4 | NCT04124939 Comparator | Nov 2019 → Nov 2022 | overactive bladder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT04148872 Comparator | Oct 2019 → Aug 2021 | cranial nerve neuropathy | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT03654066 Comparator | May 2019 → Jun 2026 overdue | achalasia | Vanderbilt University Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03712449 Background | Jan 2019 → Jul 2020 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT03698409 Comparator | Jan → Aug 2019 | migraine disorder | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03136341 Comparator | Dec 2018 → Dec 2022 overdue | movement disorder | David M. Simpson | Recruiting | No outcome recorded |
| Phase 4 | NCT03860662 Comparator | May 2018 → Mar 2019 | spastic hemiplegia, stroke disorder | Mustafa Kemal University | Completed | No outcome recorded |
| Phase 4 | NCT03052764 Comparator | Dec 2016 → Dec 2018 | overactive bladder | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02942303 Comparator | Oct 2016 → May 2017 | Tented eyebrows | St Joseph University, Beirut, Lebanon | Unknown | No outcome recorded |
| Phase 4 | NCT02678377 Comparator | Feb 2016 → Jul 2021 | female stress incontinence, overactive bladder | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT02600715 Background | Nov 2015 → Jun 2017 | interstitial cystitis, overactive bladder | Edgar LeClaire, MD | Completed | No outcome recorded |
| Phase 4 | NCT03508882 Comparator | Jul 2015 → Oct 2017 | benign essential blepharospasm, facial spasm | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT02462317 Comparator | Apr 2015 → Dec 2019 | — | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT03044080 Comparator | Jan 2015 → Jun 2017 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 4 | NCT02321436 Comparator | Dec 2014 → Mar 2016 | spastic monoplegia, stroke disorder | Ipsen | Completed | No outcome recorded |
| Phase 4 | NCT02177617 Comparator | Dec 2014 → Jan 2017 | cervical dystonia | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT01583478 Comparator | Sep 2014 → Oct 2015 | elastoderma, skin atrophy | The Maas Clinic | Unknown | No outcome recorded |
| Phase 4 | NCT02191579 Comparator | Aug 2014 → May 2017 | migraine disorder | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02052024 Comparator | May 2014 → Aug 2015 | brain injury, neoplasm, spinal cord injury, stroke disorder | Georgetown University | Completed | No outcome recorded |
| Phase 4 | NCT02114736 Comparator | Mar 2014 → Dec 2017 | stroke disorder | University Hospital of Mont-Godinne | Unknown | No outcome recorded |
| Phase 4 | NCT02096081 Comparator | Feb → Aug 2014 | — | Merz North America, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02009540 Comparator | Dec 2013 → Jan 2014 | overactive bladder | Mr HD Flood | Unknown | No outcome recorded |
| Phase 4 | NCT01968902 Comparator | Nov 2013 → Jan 2016 | multiple sclerosis | Multiple Sclerosis Center of Northeastern New York | Completed | No outcome recorded |
| Phase 4 | NCT01860196 Comparator | Jun 2013 → Mar 2017 | cerebral palsy | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01777620 Comparator | Jan → May 2013 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01700387 Background | Oct 2012 → Aug 2014 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01698138 Comparator | Sep 2012 → Dec 2020 | overactive bladder, spinal cord injury | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01678001 Comparator | Aug 2012 → Aug 2016 | plantar fasciitis | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| Phase 4 | NCT03048383 Comparator | Jul 2012 → Mar 2015 | facial nerve disorder | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT01579500 Comparator | Apr 2012 → Apr 2013 | neuropathy, painful, spinal cord injury | Catholic University of Korea Saint Paul's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01486264 Comparator | Jan 2012 → Mar 2016 | cervical dystonia | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01500668 Comparator | Jan 2012 → Dec 2013 | Nicolau syndrome | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01728337 Comparator | Jul 2011 → Feb 2012 | — | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01391312 Comparator | Jun → Oct 2011 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01308593 Comparator | Mar → Oct 2011 | ptosis | Skin Care and Laser Physicians of Beverly Hills | Completed | No outcome recorded |
| Phase 4 | NCT01336439 Comparator | Mar → Aug 2011 | parasomnia, sleep bruxism type | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT01556971 Comparator | Feb 2011 → Jun 2012 | major depressive disorder | Capital Clinical Research Associates, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT01269801 Comparator | Jan → Sep 2011 | — | AboutSkin Dermatology and DermSurgery, PC | Completed | No outcome recorded |
| Phase 4 | NCT01732809 Comparator | Jan → Nov 2011 | skin atrophy | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01251211 Comparator | Oct 2010 → Jan 2014 | diabetic polyneuropathy, polyneuropathy, postherpetic neuralgia | Hospital Ambroise Paré Paris | Completed | No outcome recorded |
| Phase 4 | NCT01271452 Comparator | Sep 2010 → Jan 2011 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01501500 Comparator | Aug 2010 → Aug 2013 | toe, misshapen | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01071096 Comparator | Jun 2010 → Jun 2011 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01157507 Comparator | Jan 2010 → Sep 2011 | interstitial cystitis | University Of Perugia | Unknown | No outcome recorded |
| Phase 4 | NCT01004042 Comparator | Oct 2009 → Mar 2010 | depressive disorder | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01529788 Comparator | Sep 2009 → Sep 2012 | dermis disorder, skin atrophy | The Maas Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00669474 Comparator | Jun 2009 → Aug 2011 | isolated hyperchlorhidrosis | University Hospital, Ghent | Terminated | No outcome recorded |
| Phase 4 | NCT01051687 Comparator | Apr 2009 → Jan 2010 | vitiligo | King Saud University | Completed | No outcome recorded |
| Phase 4 | NCT00908050 Comparator | Apr 2009 → Aug 2011 | bruxism | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00549783 Comparator | Oct 2007 → Jan 2010 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00528541 Comparator | Sep 2007 → Sep 2009 | cervical dystonia | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00432341 Comparator | Jun 2007 → Mar 2009 | cervical dystonia | Allergan | Terminated | No outcome recorded |
| Phase 4 | NCT01460355 Comparator | Sep 2006 → Jun 2007 | esotropia, exotropia | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT00761592 Comparator | Jul 2006 → Jan 2008 | benign essential blepharospasm | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00320281 Comparator | Apr 2006 → Aug 2008 | spinal cord injury | Craig Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00959907 Comparator | May 2005 → Nov 2007 | — | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase not applicable41 trials | ||||||
| — | NCT05765071 Comparator | Jul 2025 → Jun 2028 expected | compartment syndrome | University of Calgary | Recruiting | No outcome recorded |
| — | NCT07184307 Comparator | Apr 2025 → Apr 2026 overdue | overactive bladder | Benha University | Recruiting | No outcome recorded |
| — | NCT07715331 Comparator | Jan 2025 → Feb 2026 | gingival disorder | Al-Azhar University | Completed | No outcome recorded |
| — | NCT07360483 Comparator | Jan → May 2025 | — | Cairo University | Completed | No outcome recorded |
| — | NCT06684249 Comparator | Nov 2024 → May 2025 overdue | migraine disorder | Zagazig University | Recruiting | No outcome recorded |
| — | NCT06094309 Comparator | Jun 2024 | Parkinson disease, salivary substance, Clostridium botulinum type | Centro Hospitalar de Lisboa Central | Unknown | No outcome recorded |
| — | NCT07331844 Comparator | May 2024 → Feb 2025 | ischemic stroke, spastic hemiplegia | Fatih Sultan Mehmet Training and Research Hospital | Completed | No outcome recorded |
| — | NCT06544993 Comparator | May 2024 → Apr 2025 overdue | skin atrophy | Sohag University | Recruiting | No outcome recorded |
| — | NCT06207955 Comparator | Feb → Dec 2024 | temporomandibular joint disorder | Fayoum University | Unknown | No outcome recorded |
| — | NCT05874154 Comparator | Jan 2024 → Mar 2027 expected | stroke disorder | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| — | NCT06437899 Comparator | Sep 2023 → Sep 2026 expected | overactive bladder | Hospital LKH Hochsteiermark - Leoben | Enrolling by invitation | No outcome recorded |
| — | NCT04994990 Comparator | May 2023 → Nov 2024 | — | Northwell Health | Withdrawn | No outcome recorded |
| — | NCT05627921 Background | Nov 2022 → Jul 2023 | spastic cerebral palsy | Marmara University | Unknown | No outcome recorded |
| — | NCT04938102 Comparator | Jul 2022 → Jul 2023 | esophageal disorder | University of Kansas Medical Center | Withdrawn | No outcome recorded |
| — | NCT05167864 Comparator | Mar 2022 → Jun 2023 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT05099835 Comparator | Nov 2021 → Jun 2022 | — | Assiut University | Completed | No outcome recorded |
| — | NCT06392633 Comparator | Jan 2021 → Jun 2024 | stroke disorder | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | Unknown | No outcome recorded |
| — | NCT04422197 Comparator | Jun 2020 → Dec 2021 | — | Mansoura University | Unknown | No outcome recorded |
| — | NCT03920449 Comparator | May 2019 → Dec 2020 | ulcer of anus and rectum | Mansoura University | Unknown | No outcome recorded |
| — | NCT02995967 Comparator | Nov 2016 → Dec 2017 | overactive bladder | University of Alabama at Birmingham | Terminated | No outcome recorded |
| — | NCT03508869 Comparator | Sep 2016 → Sep 2017 | rosacea | Skin Laser & Surgery Specialists | Terminated | No outcome recorded |
| — | NCT03054480 Comparator | Aug → Dec 2016 | isolated hyperchlorhidrosis | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| — | NCT02196155 Comparator | Jul 2016 → Dec 2026 expected | plantar fasciitis | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| — | NCT05027243 Background | Jan 2016 → Jun 2021 | temporomandibular joint disorder | Instituto Portugues da Face | Completed | No outcome recorded |
| — | NCT02953015 Background | Jan → Sep 2016 | headache disorder | University of Verona | Unknown | No outcome recorded |
| — | NCT03533062 Comparator | Jun 2015 → Oct 2016 | overactive bladder, poisoning | Mansoura University | Completed | No outcome recorded |
| — | NCT01905137 Comparator | Jul 2013 → Mar 2018 | myofascial pain syndrome | Boston Urogynecology Associates | Unknown | No outcome recorded |
| — | NCT02327728 Comparator | Feb 2013 → Dec 2015 | benign essential blepharospasm | YangHui | Unknown | No outcome recorded |
| — | NCT02051933 Comparator | Jan 2013 → Mar 2016 | congenital contractures | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| — | NCT01691651 Comparator | Sep 2012 → Oct 2014 | keratoconus | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT02122536 Comparator | Jul → Nov 2012 | — | YMD Eye and Face | Completed | No outcome recorded |
| — | NCT01391299 Comparator | Jun → Oct 2011 | — | Allergan | Completed | No outcome recorded |
| — | NCT01233999 Comparator | Oct 2010 → Oct 2011 | Raynaud disease | Emory University | Completed | No outcome recorded |
| — | NCT01412008 Comparator | Mar 2010 → Jun 2012 | stroke disorder | New York Presbyterian Hospital | Completed | No outcome recorded |
| — | NCT01432782 Comparator | Feb 2010 → Dec 2013 | dyskinesia of esophagus | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| — | NCT00930709 Comparator | Mar 2009 → Dec 2014 | epicondylitis | Seinajoki Central Hospital | Completed | No outcome recorded |
| — | NCT00945295 Comparator | Jan 2009 → May 2012 | — | JoAnn Harnar | Completed | No outcome recorded |
| — | NCT01477736 Comparator | Jan 2009 → Nov 2010 | spinal cord injury | Centro de Reabilitação e Readaptação Dr. Henrique Santillo | Completed | No outcome recorded |
| — | NCT00628472 Background | Jan → May 2007 | — | Henry Ford Health System | Completed | No outcome recorded |
| — | NCT00989209 Comparator | Jan → Dec 2005 | facial paralysis | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT00372970 Comparator | Jul 2003 → Dec 2008 | gastroparesis | Temple University | Completed | No outcome recorded |
Press releases naming this drug 54 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-04 | AbbVie | Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence abbvie.com ↗ |
| 2026-07-17 | AbbVie | Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients abbvie.com ↗ |
| 2026-07-09 | Ipsen | Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. ipsen.com ↗ |
| 2026-06-24 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 abbvie.com ↗ |
| 2026-06-23 | AbbVie | Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients abbvie.com ↗ |
| 2026-05-19 | Ipsen | Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity ipsen.com ↗ |
| 2026-04-08 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year abbvie.com ↗ |
| 2025-10-29 | AbbVie | The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year abbvie.com ↗ |
| 2025-10-06 | AbbVie | AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor abbvie.com ↗ |
| 2025-09-09 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories abbvie.com ↗ |
| 2024-11-07 | AbbVie | Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day abbvie.com ↗ |
| 2024-10-18 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) abbvie.com ↗ |
| 2024-09-24 | AbbVie | Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns abbvie.com ↗ |
| 2024-09-11 | AbbVie | Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China abbvie.com ↗ |
| 2024-06-11 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients abbvie.com ↗ |
| 2024-04-23 | AbbVie | Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands abbvie.com ↗ |
| 2024-02-21 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs abbvie.com ↗ |
| 2024-01-19 | Ipsen | TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA ipsen.com ↗ |
| 2023-11-20 | AbbVie | Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever abbvie.com ↗ |
| 2023-11-01 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before abbvie.com ↗ |
| 2023-09-18 | AbbVie | Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence abbvie.com ↗ |
| 2023-09-06 | AbbVie | Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs abbvie.com ↗ |
| 2023-08-30 | AbbVie | Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic) abbvie.com ↗ |
| 2023-08-23 | Ipsen | TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications ipsen.com ↗ |
| 2023-06-13 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program abbvie.com ↗ |
| 2023-03-08 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs abbvie.com ↗ |
| 2022-11-17 | AbbVie | Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet abbvie.com ↗ |
| 2022-11-07 | AbbVie | AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients abbvie.com ↗ |
| 2022-11-02 | AbbVie | Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day abbvie.com ↗ |
| 2022-09-13 | AbbVie | Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories abbvie.com ↗ |
| 2022-07-25 | AbbVie | AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference abbvie.com ↗ |
| 2022-06-09 | Ipsen | Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury ipsen.com ↗ |
| 2022-04-13 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval abbvie.com ↗ |
| 2022-01-24 | AbbVie | Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA) abbvie.com ↗ |
| 2021-11-15 | AbbVie | Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day abbvie.com ↗ |
| 2021-07-29 | AbbVie | FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity abbvie.com ↗ |
| 2021-06-08 | AbbVie | Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign abbvie.com ↗ |
| 2021-02-10 | AbbVie | BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition abbvie.com ↗ |
| 2021-01-15 | Ipsen | TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications ipsen.com ↗ |
| 2021-01-15 | AbbVie | Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference abbvie.com ↗ |
| 2020-11-16 | AbbVie | Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day abbvie.com ↗ |
| 2020-07-09 | AbbVie | FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗ |
| 2020-06-22 | AbbVie | FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity abbvie.com ↗ |
| 2020-05-23 | Ipsen | New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence ipsen.com ↗ |
| 2020-01-06 | Ipsen | Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy ipsen.com ↗ |
| 2019-09-23 | Ipsen | Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis ipsen.com ↗ |
| 2019-06-21 | AbbVie | FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity abbvie.com ↗ |
| 2019-03-07 | AbbVie | FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity abbvie.com ↗ |
| 2019-01-28 | AbbVie | New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand abbvie.com ↗ |
| 2019-01-17 | Ipsen | Ipsen presents the results of the first in-human study of a recombinant fast-acting neurotoxin (rBoNT-E) at TOXINS 2019 ipsen.com ↗ |
| 2019-01-11 | Ipsen | Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019 ipsen.com ↗ |
| 2018-09-14 | AbbVie | Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline abbvie.com ↗ |
| 2018-09-14 | AbbVie | Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines abbvie.com ↗ |
| 2018-07-04 | Ipsen | Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research ipsen.com ↗ |
Evidence & citations 125 cited values
Every value below carries the sentence it was read from. 1,032 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botulinum toxin type A | “Since its introduction in the 1970s for the treatment of strabismus, blepharospasm, and focal dystonia, botulinum toxin type A (BTX-A) has been widely used in the treatment of...” NCT03555916 ↗345“Another recent evidence suggests an enhanced sensitization of central pain processing in patients with RLS. This had led to consider the botulinum toxin type A (BNT) as an...” NCT00949806 ↗ “The SILENCE-NEUROMA Trial is a multicenter, randomized, double-blind, active-controlled study designed to compare the efficacy and safety of botulinum toxin type A versus local...” NCT07431944 ↗ “The safety and efficacy of Mentor Purified Toxin, Botulinum Toxin Type A, Purified Neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for...” NCT00549341 ↗ “Botulinum toxin type A (BoNT-A), a peripheral neuromodulator, has been proposed as a potential therapeutic alternative by inducing chemodenervation and muscle volume reduction,...” NCT07399782 ↗ “The main objective is to evaluate the analgesic efficacy of botulinum toxin type A in refractory chronic proctalgia one month after a bilateral injection of 50 units of Botox ®...” NCT01331356 ↗ “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “Botox containing Botulinum toxin type A is a purified substance, derived from a bacterium that block muscular nerve signals temporarily preventing the muscular contraction and...” NCT05162300 ↗ “Botulinum toxin type A (BTX-A; Botox, Allergan, Inc., Irvine, CA, USA) was administered through intramuscular injection into the masseter and temporalis muscles during a single...” NCT07361900 ↗ “Botulinum toxin type A (BoNT-A) is widely used to treat muscle hyperactivity, based on its ability to inhibit synaptic exocytosis and, therefore, to disable neural transmission.” NCT05411900 ↗ “The aim was to compare the efficacy of intraarticular Botulinum toxin type A (BoNT-A) and intraarticular hyaluronate plus rehabilitation exercise in patients with ankle OA.” PMID 24502534 ↗ Feb 2014 “Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation.” PMID 18546285 ↗ Sep 2008 “Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)” NCT03779841 ↗ “Botulinum toxin type-A (BoNT-A) is often used for refractory cases unresponsive to conservative therapies; however, its biological mechanisms remain unclear.” PMID 42062988 ↗ Apr 2026 “OBJECTIVE: To compare the effects of 2 different injection sites of low doses of botulinum toxin type A with steroid in treating lateral epicondylalgia.” PMID 27666156 ↗ Sep 2016 “Treatment plan was established by utilizing thirty units of Botulinum toxin type (A) which was injected into masseter and sometimes temporalis muscle.” NCT06824324 ↗ “botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia.” NCT06470581 ↗ “The ideal dosage for botulinum toxin type A (BoNT-A), a sphincter-preserving substitute for lateral internal sphincterotomy, is still unknown.” NCT07543315 ↗ “Botulinum toxin type A (BTXA) injection is a well established, clinically effective and safe treatment for muscle spasticity in CP (2;19;20).” NCT01437644 ↗ “The purpose of this study is to determine the effectiveness of treatment of idiopathic clubfoot utilizing Botulinum Toxin Type A (Botox).” NCT00474032 ↗ “Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.” NCT01551940 ↗ “Botulinum toxin type A is a neurotoxin produced by the bacterium Clostridium botulinum which causes a flaccid muscle paralysis.” PMID 17177750 ↗ Sep 2006 “Non-randomised studies assessing intrarectal botulinum toxin type A (BoNTA) injections for faecal incontinence are promising.” PMID 38128556 ↗ Dec 2023 “Botulinum toxin type A was injected into the bulbospongiosus muscle and glans penis according to a standerdized protocol.” NCT07426640 ↗ “botulinum toxin type A (onabotulinumtoxinA; onabotA) injections to induce temporary paralysis in the glabellar muscles” PMID 36849797 ↗ Feb 2023 “Botulinum toxin type A (BOTOX®) injections will performed on an outpatient basis by cystoscopy under local anesthesia.” NCT04819360 ↗ “BOTOX®, a botulinum toxin type A produced from Clostridium botulinum, blocks certain chemicals that cause spasticity.” NCT00565201 ↗ “Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)” NCT06293300 ↗ “Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis” NCT03119948 ↗ “different doses of botulinum toxin type A (abobotulinumtoxin A) for the treatment of upper anterior gummy smile” NCT03284047 ↗ “Patients will receive a total of 20 units of botulinum toxin type A (Botox) injected into each masseter muscle.” NCT07082972 ↗ “Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report.” PMID 19357910 ↗ Apr 2009 “100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline.” NCT05620316 ↗ “Each patient received six randomized injections of botulinum toxin type A (Botox® Allergan).” NCT00628472 ↗ “the patient will receive Botulinum toxin type A followed by surgical closure of cleft lip” NCT07137234 ↗ “OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.” NCT00894517 ↗ “Botulinum toxin type A is a neurotoxin used to reduce excessive muscle contraction.” NCT06676475 ↗ “A single injection of 60 units of botulinum toxin type A or normal saline placebo.” PMID 16330790 ↗ Dec 2005 “Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache” NCT01357798 ↗ “Botulinum toxin type A is a neurotoxin derived from Clostridium botulinum culture.” NCT07013240 ↗ “botulinum toxin type A (BTX-A) treatment is an easy and fast outpatient procedure” NCT04820543 ↗ “Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex” NCT02097121 ↗ “botulinum toxin type A (BT-A) have also been demonstrated to reduce HSP” NCT01473277 ↗ “Will include 15 patients will injected with botulinum toxin type A” NCT06729840 ↗ “Botulinum Toxin Type a (Dysport®, Abobotulinum Toxin A) Injection” NCT02917967 ↗ “Micro-Botox, is a highly diluted Botulinum toxin type A” NCT06544993 ↗ “Botulinum toxin Type A topical liniment (ANT-1207).” NCT02479139 ↗ “Botulinum toxin type-A (Onabotulinum toxin type-A)” NCT04940143 ↗ “Intragastric injection of Botulinum toxin type A” NCT04274608 ↗ “Botulinum Toxin (Type A) injection (10 U/Kg)” NCT00474032 ↗ “Botulinum Toxin Type A - OnabotulinumtoxinA” NCT00661089 ↗ “Botulinum Toxin Type A (Botox) and Placebo” NCT00152347 ↗ “BOTOX Cosmetic™ (Botulinum Toxin Type A)” NCT00250952 ↗ “Intervention-Botulinum Toxin Type A” NCT01905137 ↗ “Biological: Botulinum Toxin, Type A” NCT01358695 ↗ “Meditoxin (Botulinum toxin type A)” NCT03452345 ↗ “Biological: Botulinum Toxin Type A” NCT01358695 ↗ “Botulinum toxin type A(Botox®)” NCT01791920 ↗ “Botox (Botulinum toxin type A)” NCT03908008 ↗ “botulinum toxin Type A” NCT02230956 ↗ “Botulinum toxin type A” NCT00825097 ↗ |
| Known as | 25 units botox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06851598 ↗ |
| Known as | 93094EC | “Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC” NCT04383912 ↗ |
| Known as | ABO | “Drug: AbobotulinumtoxinA (ABO)” NCT01732809 ↗ |
| Known as | abo-BoNT-A | “AIM: To define optimal (safe and efficacious) doses of abobotulinumtoxinA (aboBoNT-A) for the treatment of PVD associated with hypertonic pelvic floor muscle dysfunction and to...” PMID 39953376 ↗ Apr 20254“OBJECTIVE: To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT-A;...” PMID 32741133 ↗ Sep 2020 “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 “OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA (aboBoNT-A) for NDOI.” PMID 35400537 ↗ Apr 2022 |
| Known as | abobotulinumtoxinA | “The most commonly used subtype is toxin A commercially found as BOTOX (onabotulinumtoxinA, Allergan, approved by FDA in 1989), Dysport (abobotulinumtoxinA, Medicis, approved by...” NCT03186001 ↗49“In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation...” NCT05874154 ↗ “AIM: To define optimal (safe and efficacious) doses of abobotulinumtoxinA (aboBoNT-A) for the treatment of PVD associated with hypertonic pelvic floor muscle dysfunction and to...” PMID 39953376 ↗ Apr 2025 “This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in...” NCT03469999 ↗ “OBJECTIVE: To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT-A;...” PMID 32741133 ↗ Sep 2020 “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “Lack of head-to-head comparative safety and efficacy data for abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) represented an important gap for informed...” PMID 42159955 ↗ May 2026 “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 “The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms.” PMID 29933562 ↗ Jun 2018 “Their study designs involved repeat intramuscular injections of abobotulinumtoxinA (Dysport®), and efficacy endpoints were collected accordingly.” PMID 29781237 ↗ May 2018 “different doses of botulinum toxin type A (abobotulinumtoxin A) for the treatment of upper anterior gummy smile” NCT03284047 ↗ “AbobotulinumtoxinA solution for injection is a ready-to-use liquid formulation of abobotulinumtoxinA.” PMID 27653448 ↗ Sep 2016 “Two Botulinum Type A Exotoxins (Onabotulinum Toxin A and Abobotulinum Toxin A)” NCT01529788 ↗ “The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon” NCT03639766 ↗ “75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU” NCT02909907 ↗ “Botulinum Toxin Type a (Dysport®, Abobotulinum Toxin A) Injection” NCT02917967 ↗ “1 dose of 60 units of abobotulinum toxin A (ABoNT/A);” PMID 40434770 ↗ Jul 2025 “AbobotulinumtoxinA: 50 (Speywood) units” NCT06448676 ↗ “AbobotulinumtoxinA (DysportRU®)” NCT01333397 ↗ “abobotulinumtoxinA (Dysport®)” NCT04970407 ↗ “AbobotulinumtoxinA (Dysport®)” NCT02106351 ↗ “AbobotulinumtoxinA (Dysport®)” NCT03663101 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00234507 ↗ “AbobotulinumtoxinA (Dysport®)” NCT02450526 ↗ |
| Known as | AbobotulinumtoxinA (Azzalure) | “AbobotulinumtoxinA (Azzalure®)” NCT01333397 ↗ |
| Known as | AbobotulinumtoxinA (Dysport) | “AbobotulinumtoxinA (Dysport®)” NCT00234507 ↗15“AbobotulinumtoxinA (Dysport®)” NCT03663101 ↗ “AbobotulinumtoxinA (Dysport®)” NCT02450526 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00257660 ↗ “AbobotulinumtoxinA (Dysport®)” NCT03569098 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01251367 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00210444 ↗ “AbobotulinumtoxinA (Dysport®)” NCT02321436 ↗ “AbobotulinumtoxinA (Dysport®)” NCT02106351 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01249417 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01313312 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01313299 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01261611 ↗ “abobotulinumtoxinA (Dysport®)” NCT04970407 ↗ “AbobotulinumtoxinA (Dysport®)” NCT03598777 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00455637 ↗ |
| Known as | AbobotulinumtoxinA (DysportRU) | “AbobotulinumtoxinA (DysportRU®)” NCT01333397 ↗1“AbobotulinumtoxinA (DysportRU®)” NCT01261611 ↗ |
| Known as | aboboutlinum toxin A | “This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the...” NCT03639766 ↗ |
| Known as | ABoNT/A | “1 dose of 60 units of abobotulinum toxin A (ABoNT/A);” PMID 40434770 ↗ Jul 2025 |
| Known as | AGN 151607 | “Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)” NCT03779841 ↗ |
| Known as | ANT-1207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479139 ↗ |
| Known as | ANT-1401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01809964 ↗ |
| Known as | ANT-1403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01799824 ↗ |
| Known as | Azzalure | “Botulinum Toxin Type A (Azzalure)” NCT01529203 ↗ |
| Known as | Bao Tuo Shi | “Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)” NCT05380154 ↗ |
| Known as | BNT | “Recently, botulinum toxin type A (BNT) has been reported to relief RLS in patients with severe symptoms but this was not confirmed by other anecdotal reports.” NCT00949806 ↗ |
| Known as | Bocouture | “IncobotulinumtoxinA (NT 201,
Xeomin/Xeomeen/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) is a
150-kDa botulinum toxin type A free of complexing proteins.” PMID 23379292 ↗ Feb 20131“NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).” NCT00777803 ↗ |
| Known as | BoNT | “Onabotulinumtoxin A (BoNT)” NCT02600715 ↗ |
| Known as | BoNT A1 = Dysport | “BoNT A1 = Dysport” NCT00959907 ↗ |
| Known as | BoNT A2 = Botox | “BoNT A2 = Botox” NCT00959907 ↗ |
| Known as | BoNT-A | “AIM: To assess the effect of single botulinum neurotoxin A (BoNT-A) injections into the calf muscles on the gross energy cost of walking in children with cerebral palsy (CP)...” PMID 39058740 ↗ Jul 202444“Although numerous articles were published on the Botulinum Toxin A (BoNTA) injection in the management of MPS, but there were diverse clinical results in the literature...” NCT06824324 ↗ “Botulinum toxin type A (BoNT-A), a peripheral neuromodulator, has been proposed as a potential therapeutic alternative by inducing chemodenervation and muscle volume reduction,...” NCT07399782 ↗ “Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic...” NCT03704155 ↗ “Participants with a Modified Ashworth Scale (MAS) score of 1+ or above received BoNT-A (Dysport) 500 U or placebo to one or more wrist and elbow mover muscles, plus...” PMID 22371239 ↗ Feb 2012 “OBJECTIVE: To investigate whether extracorporeal shock wave therapy (ESWT) is noninferior to botulinum toxin type A (BoNT-A) for the treatment of poststroke upper limb spasticity.” PMID 30392753 ↗ Jul 2018 “Botulinum Neurotoxin-A (BoNT-A), when applied intramuscularly, inhibits presynaptic acetylcholine (Ach) release by preventing the fusion of Ach vesicles with the plasma membrane.” NCT06583343 ↗ “The aim was to compare the efficacy of intraarticular Botulinum toxin type A (BoNT-A) and intraarticular hyaluronate plus rehabilitation exercise in patients with ankle OA.” PMID 24502534 ↗ Feb 2014 “Botulinum toxin type-A (BoNT-A) is often used for refractory cases unresponsive to conservative therapies; however, its biological mechanisms remain unclear.” PMID 42062988 ↗ Apr 2026 “Botulinum toxin A (BoNT-A) injection is one of the most widely used methods for hemifacial spasm (HFS) with high efficacy in controlling spasm.” PMID 27431279 ↗ Jul 2016 “OBJECTIVE: To assess the efficacy of intradermally injected botulinum neurotoxin type A (BoNT/A) in patients with Restless Legs Syndrome (RLS).” PMID 23063302 ↗ Oct 2012 “The ideal dosage for botulinum toxin type A (BoNT-A), a sphincter-preserving substitute for lateral internal sphincterotomy, is still unknown.” NCT07543315 ↗ “Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.” NCT06203470 ↗ “Intramuscular injections of botulinum toxin A (BoNT-A) have shown an analgesic effect on LBP in two previous randomized controlled studies.” PMID 29141611 ↗ Nov 2017 “botulinum toxin (BoNT-A) interventions prospectively compared to find out the effect of BoNT-A injection on myofascial pain syndrome (MPS).” NCT06899438 ↗ “Intravesical onabotulinumtoxinA (BoNT-A) injection can relieve symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS).” PMID 29331031 ↗ Jan 2018 “intramuscular injection of 100U botulinum toxin (BoNT-A) is a reasonable choice for the treatment of bladder overactivity in PD” NCT05997043 ↗ “Non-randomised studies assessing intrarectal botulinum toxin type A (BoNTA) injections for faecal incontinence are promising.” PMID 38128556 ↗ Dec 2023 “Botulinum toxin type A (BoNT-A) is an exotoxin released by the Gram-positive, anaerobic bacillus Clostridium botulinum” NCT03331913 ↗ “Intravesical botulinum toxin A (BoNT-A) has recently emerged as novel treatment for OAB refractory to antimuscarinics” NCT01167257 ↗ “Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)” NCT06293300 ↗ “At the moment Onabotulinum toxin A (BoNT-A) represents the only drug specifically approved for CM prophylaxis.” NCT04578782 ↗ “Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles” NCT06218316 ↗ “Botulinum toxin A (BoNT-A) is used as an alternative treatment for chronic orthopedic conditions.” PMID 22673486 ↗ Jul 2012 “Botulinum toxin A (BoNT-A) is a novel treatment for chronic lateral epicondylar tendinopathy.” PMID 29762276 ↗ May 2018 “Botulinum toxin type A (BoNT-A) has shown potential in relieving chronic muscular pain.” PMID 41487935 ↗ Dec 2025 “Encouraging results were reported with the use of botulinum neurotoxin-A (BoNT-A).” PMID 26808752 ↗ Sep 2016 “injection of onabotulinumtoxinA 100 U (BoNT-A, Allergan, Irvine, California, USA)” NCT01657409 ↗ “BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).” NCT06793683 ↗ “Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection” NCT07070817 ↗ “botulinum toxin type A (BoNT-A) on cervical dystonia (CD) motor symptoms” PMID 23604344 ↗ Apr 2013 “Botulinum Neurotoxin Type A (BoNT-A) prostatic injection” PMID 29383480 ↗ Jan 2018 “Drug: Botulinum Toxin Type A (BoNT-A)” NCT07626983 ↗ “Botulinum Toxin Type A (BoNT-A)” NCT07645456 ↗ “botulinum toxin type A (BoNT/A)” NCT00451191 ↗ “botulinum toxin type A(BoNT-A)” NCT01276015 ↗ “Botulinum toxin A (BoNT-A) 50U” NCT02425176 ↗ “Botulinum toxin type A, BoNT-A” NCT00945295 ↗ “Botulinum toxin A ( BoNT-A)” NCT02832713 ↗ |
| Known as | BoNT-A (BOTOX 300U) | “BoNT-A (BOTOX 300U)” NCT01682603 ↗ |
| Known as | BoTN | “STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines?” NCT05766683 ↗ |
| Known as | BoTN/A | “Observational data suggest that intrapyloric injection of botulinum toxin A (BoTN/A) reduces symptoms and accelerates gastric emptying in idiopathic and diabetic gastroparesis.” PMID 18070232 ↗ Dec 2007 |
| Known as | Botox | “Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®,...” NCT07013240 ↗240“The primary objective of this study is to determine whether intramuscular injections of botulinum toxin type A (Botox®) in selected cervical muscles at antidystonic dosages can...” NCT00477802 ↗ “Patients were randomly assigned (1:1) by a central web form to receive intrarectal submucosal injections of either 200 units of BoNTA (Botox; Allergan, Irvine, CA, USA; BoNTA...” PMID 38128556 ↗ Dec 2023 “Treatment consisted of a multimodal approach including intravaginal injections of onabotulinumtoxinA (Botox) and bupivacaine, progressive dilation under conscious sedation,...” PMID 28363809 ↗ Mar 2017 “This is a randomised, double-blind, intra-individual controlled, dose escalation study to assess the safety, tolerability and preliminary effectiveness of a single dose of...” NCT03796351 ↗ “The botulinum toxin (BOTOX®), which can exert a paralytic effect by binding to presynaptic cholinergic nerve terminals at the neuromuscular junction, is produced by the...” NCT06974617 ↗ “The current study will investigate the comparative efficacy, safety and patient satisfaction of intradetrusor injections BOTOX® injections (200U) versus placebo (saline)...” NCT00479596 ↗ “The BTX-A group will receive onabotulinumtoxinA (Botox®, Allergan) with mandatory muscles getting 300 units and optional muscles getting up to 100 additional units (maximum...” NCT06296082 ↗ “Multicenter, Double-blind, Randomized, Parallel Design, Active-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of 100 Units of BMI 2006 and Botox® in...” NCT05531968 ↗ “A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified...” NCT03915067 ↗ “The study has been designed to test the superiority of QM1114-DP compared to placebo, and the non-inferior efficacy of QM1114-DP compared to onabotulinumtoxinA (BOTOX®), in...” NCT05463965 ↗ “Botulinum toxin (Botox, Allergan) is an inhibitor of cholinergic neuromuscular transmission and has been used to treat spastic disorders of both striated and smooth muscles by...” NCT00372970 ↗ “A Prospective, Randomized, Multi-center, Phase III, Double-Blind, Activi Controlled, Parallel-group Study to Evaliate the Efficacy and Safety of MEDITOXIN® Comparison With...” NCT03905304 ↗ “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “The study has been designed to test the safety,efficacy,immunogenicity of YY001,and compare to onabotulinumtoxinA (BOTOX®) and placebo, in improving the appearance of moderate...” NCT05743634 ↗ “The patient will benefit from an ultrasound guided injection of botulinum toxin A (Botox®) or placebo (NaCl 0.9 %) and will be followed up in consultation at 4, 12, 16 (if...” NCT01551940 ↗ “This is a randomized controlled trial to compare intra-gastric injection of Botulinum Toxin A (Botox; Allergan Inc. Irvine, Ca, USA) against non-surgical management for obesity...” NCT04274608 ↗ “We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of...” PMID 25476727 ↗ Dec 2014 “A total of 300U BTX-A (BOTOX, 100 U/vial, Allergan Co., Irvine, USA) dissolved into 30 mL normal saline will be injected into 30 sites of the bladder including lateral,...” NCT01682603 ↗ “The study aimed to assess the efficacy of type A botulinum toxin (Botox, Allergan, Inc. Irvine, CA) to treat myofascial pain symptoms and to reduce muscle hyperactivity in bruxers.” PMID 18468272 ↗ Apr 2008 “This study will examine the efficacy of Botulinum Toxin Type A ("Botox") in treating Allodynic-type neuropathic pain in people with spinal cord injury or multiple sclerosis.” NCT01911377 ↗ “Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day” NCT01167257 ↗ “The purpose of this study is to evaluate the effect of BOTOX® (OnabotulinumtoxinA) on the number of headache days in patients with New Daily Persistent Headache (NDPH).” NCT01920945 ↗ “Participants in this arm received an ultrasound-guided injection of 7 mL containing 35 units of botulinum toxin type A (BOTOX) into the lateral pterygoid muscle.” NCT07385742 ↗ “Assessing the Safety and Efficacy of Utilizing CGRPmAb Fremanezumab (Ajovy) in Chronic Migraine Patients Currently on Monotherapy OnabotulinumtoxinA (Botox).” NCT05724771 ↗ “Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation.” NCT02044302 ↗ “We evaluated the efficacy and safety of Neuronox (Neu-BoNT/A) compared with BOTOX (onabotulinum toxin A) for treating post-stroke upper limb spasticity.” PMID 26030192 ↗ Jun 2015 “To compare the efficacy and safety of MT10107 (Coretox) with those of onabotulinum toxin A (Botox) in patients with poststroke upper limb spasticity” PMID 32497599 ↗ Jun 2020 “This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children.” NCT00060957 ↗ “Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet.” NCT03796351 ↗ “A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines” NCT04081402 ↗ “Phase 1b Safety and Tolerability of Intradermal BOTOX® (OnabotulinumtoxinA) Purified Neurotoxin Complex in Participants With Facial Fine Lines” NCT04631588 ↗ “The purpose of this study is to determine the effectiveness of treatment of idiopathic clubfoot utilizing Botulinum Toxin Type A (Botox).” NCT00474032 ↗ “Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.” NCT00908050 ↗ “treatment with botulinum toxin-A (BOTOX; Allergan, Inc.), may ameliorate the severe paroxysmal pain of symptomatic cutaneous leiomyomas.” NCT00971620 ↗ “This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.” NCT01603615 ↗ “Nasri and colleagues first proposed thyroarytenoid botulinum toxin type A (BOTOX) injections for vocal fold granulomas with success.” NCT01678053 ↗ “A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.” NCT01177358 ↗ “50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection” NCT03555916 ↗ “OnabotulinumtoxinA (Botox) 200u will be reconstituted using 4 ml of preservative-free saline, as recommended by the manufacturer.” NCT03698409 ↗ “Botulinum toxin A (Botox; Allergan Incorporated, Irvine, CA, USA) was injected using a tuberculin syringe with a 27-gauge needle.” PMID 23444480 ↗ Feb 2013 “50 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle” NCT04695600 ↗ “To Confirm the non-inferiority of CUNOX® to BOTOX® in the glabellar line improvement of moderate to severe glabellar lines.” NCT03837561 ↗ “Patient would receive Botulinum toxin (Injections of 100\~400U of Botox in the upper limb muscle with a 2ml/100U dilution).” NCT04502264 ↗ “intra-articular injection of onabotulinumtoxinA (Botox® ) with those of a single intra-articular injection of normal saline” NCT06902805 ↗ “injections of botulinum toxin A (Botox) as the treatment for knee flexion contracture after total knee arthroplasty (TKA)” NCT01829087 ↗ “injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses” NCT03317717 ↗ “BOTOX®, a botulinum toxin type A produced from Clostridium botulinum, blocks certain chemicals that cause spasticity.” NCT00565201 ↗ “There are two formulations of BoNT-A available: Botox®/Vistabel®, Allergan and Dysport®/Azzalure®, Ipsen - Galderma” NCT01014871 ↗ “Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points” NCT04940143 ↗ “Patients will receive a total of 20 units of botulinum toxin type A (Botox) injected into each masseter muscle.” NCT07082972 ↗ “BOTOX® 100 U, botulinum toxin A injections in each hand or foot, for a final dose of 50 U (1 ml) per extremity” NCT05698979 ↗ “Description of Study Agent: botulinum toxin type A (Botox®) 100 International Units by intramuscular injection” NCT04750291 ↗ “100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline.” NCT05620316 ↗ “Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90” NCT00711087 ↗ “Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units” NCT00408798 ↗ “The BoNT-A will be purchased from Allergan Company (Botox, 100 units/vial, Irvine, California, U.S.A.).” NCT01733290 ↗ “As an alternative to strabismus surgery, botulinum toxin (Botox) can be applied in extraocular muscles.” NCT03459092 ↗ “Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline” NCT00178646 ↗ “Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1.” NCT00959907 ↗ “200 U intradetrusor injected OnabotulinumtoxinA (Botox®, Allergan, Inc.) (20 sites, trigone sparing)” NCT02298660 ↗ “Fifteen subjects will be randomized to receive BOTOX® and fifteen will receive placebo injections.” NCT01350375 ↗ “Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy” NCT01325090 ↗ “This novel treatment method involves the use of botulinum toxin type A (Botox).” NCT00732680 ↗ “Instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder” NCT02735499 ↗ “pattern of application of BOTULINUM TOXIN TYPE-A Botox® in the frontal area.” NCT01297634 ↗ “Specifically, we will study botulinum toxin type A BTX-A, brand name Botox.” NCT03236012 ↗ “Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode” NCT05382832 ↗ “Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30” NCT02074150 ↗ “Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb.” NCT01500668 ↗ “Botulinum toxin (200U Botox) injection in the rectus femoris muscle” NCT02114736 ↗ “Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/)” NCT03097835 ↗ “Botulinum toxin injection: Botox injections will be intradermal.” NCT06203470 ↗ “BTX-A used in this study will be Botox® and delivered in vials.” NCT06839118 ↗ “Drug: Botox® treatment for Moderate to Severe Glabellar Striae” NCT06585696 ↗ “Botox® (onabotulinumtoxin A),injections in the calf muscles.” NCT02546999 ↗ “botulinum toxin Type A (Botox ®; Allergan, Irvine, CA, USA)” NCT03799484 ↗ “100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)” NCT05099835 ↗ “Use of botulinum toxin type A for injection (Botox)” NCT06282679 ↗ “injections of Botox (botulinum toxin type A)” NCT00178945 ↗ “Biological: Botulinum toxin type A(Botox®)” NCT01915459 ↗ “Botulinum toxin type A (Botox®, Allergan)” NCT07331844 ↗ “Botulinum toxin type A (Botox®, Allergan)” NCT07360483 ↗ “Botulinum Toxin Type A Injection [Botox]” NCT05072821 ↗ “Botulinum Toxin Type A Injection [Botox]” NCT04938102 ↗ “Botulinum Toxin Type A (BOTOX) Injection” NCT07665528 ↗ “Botulinum Toxin Type A (BOTOX) Injection” NCT07568314 ↗ “Botulinum Toxin Type A Injection [Botox]” NCT07295288 ↗ “Botulinum Toxin Type A injection (BOTOX)” NCT00444886 ↗ “OnabotulinumtoxinA (Botox®) Injections” NCT06778421 ↗ “OnabotulinumtoxinA 100 UNT [Botox]” NCT03758235 ↗ “OnabotulinumtoxinA 100 UNT [Botox]” NCT05308979 ↗ “Drug: Botulinum Toxin A (Botox )” NCT06724250 ↗ “Botox (Botulinum toxin type A)” NCT03908008 ↗ “Botulinum Toxin Type A(Botox®)” NCT01791881 ↗ “Botulinum toxin type A (Botox)” NCT00432055 ↗ “Botulinum Toxin type a (Botox)” NCT07076355 ↗ “Botulinum Toxin type a (Botox)” NCT00282958 ↗ “Botulinum Toxin Type A(Botox®)” NCT01237977 ↗ “Botox®: Botulinum toxin type A” NCT01945684 ↗ “Botulinum Toxin Type A/Botox®” NCT00989768 ↗ “OnabotulinumtoxinA (Botox ®)” NCT03044080 ↗ “Botulinum toxin type A Botox” NCT02400619 ↗ “Botox (onabotulinumtoxinA)” NCT01930604 ↗ “OnabotulinumtoxinA (Botox)” NCT06937944 ↗ “Botulinum Toxin A (Botox )” NCT07549113 ↗ “Botulinum Toxin A (Botox )” NCT06785844 ↗ “Botulinum Toxin A (Botox )” NCT00231491 ↗ “Botulinum Toxin A (Botox )” NCT06840730 ↗ “Botulinum Toxin A (Botox )” NCT06721520 ↗ “Botulinum Toxin A (Botox )” NCT07545200 ↗ “Botulinum Toxin A (Botox)” NCT00194623 ↗ “Drug: Botox” NCT03181802 ↗ “BOTOX®” NCT01107392 ↗ “Botox” NCT06684249 ↗ “Botox” NCT02662972 ↗ “Botox” NCT02037425 ↗ |
| Known as | Botox (onabotulinumtoxinA) | “Botox (onabotulinumtoxinA)” NCT02074150 ↗3“Botox (onabotulinumtoxinA)” NCT02074163 ↗ “Botox (onabotulinumtoxinA)” NCT02074293 ↗ “BOTOX® OnabotulinumtoxinA” NCT01603615 ↗ |
| Known as | Botox (onabotulinumtoxinA)injection | “Botox® (onabotulinumtoxinA)injection” NCT00950664 ↗ |
| Known as | Botox , "Allergan" | “Botox ®, "Allergan"” NCT01698138 ↗1“Botox (Allergan)” NCT01589471 ↗ |
| Known as | BOTOX Cosmetic | “onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.” NCT02176356 ↗8“Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug).” NCT05162300 ↗ “Botox® Cosmetic (Allergan, Irvine, CA), is the first FDA-approved Botulinum toxin type A” NCT01529788 ↗ “BOTOX® Cosmetic is approved and commercially available for use in Canada.” NCT05138835 ↗ “Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/)” NCT03097835 ↗ “1. BOTOX Cosmetic (onabotulinumtoxinA) for Injection” NCT01269801 ↗ |
| Known as | Botox Inj | “To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of...” NCT01787344 ↗1“Botox Inj(Clostridium botulinum type A)” NCT04081402 ↗ |
| Known as | Botox Injectable Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06013644 ↗ |
| Known as | BOTOX(c) | “The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard...” NCT05512039 ↗ |
| Known as | Botox-A | “We present the rationale for and design of a randomized, open-label, active-control trial comparing the effectiveness of 200 units of onabotulinum toxin A (Botox A®) versus...” PMID 24486637 ↗ Jan 20149“Botulinum toxin-A (Botox-A) is used as pharmacologic agent not only for aesthetic purposes, but also for its vasomotor actions.” PMID 27997734 ↗ Jan 2017 “A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe.” NCT06553950 ↗ “Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC” NCT04383912 ↗ “botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease” NCT01421719 ↗ “intralesional Botox-A (100 U vacuum-dried powder in a single-use vial” NCT06230146 ↗ |
| Known as | Botulax | “Biological: Botulinum toxin type A(Botulax®)” NCT01915459 ↗ |
| Known as | Botulax Inj. | “To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of...” NCT01787344 ↗ |
| Known as | Botulift | “botulinum toxin Botulift® (botulinum toxin type A)” NCT03812965 ↗ |
| Known as | Botulinum Neurotoxin Type A | “OBJECTIVE: To assess the efficacy of intradermally injected botulinum neurotoxin type A (BoNT/A) in patients with Restless Legs Syndrome (RLS).” PMID 23063302 ↗ Oct 20126“Clinical Trial To Evaluate Botulinum Neurotoxin Type A (ANT-1207) In Subjects With Acne” NCT01293552 ↗ “Botulinum Neurotoxin Type A (BoNT-A) prostatic injection” PMID 29383480 ↗ Jan 2018 |
| Known as | Botulinum Neurotoxin-A | “AIM: To assess the effect of single botulinum neurotoxin A (BoNT-A) injections into the calf muscles on the gross energy cost of walking in children with cerebral palsy (CP)...” PMID 39058740 ↗ Jul 20243“Botulinum Neurotoxin-A (BoNT-A), when applied intramuscularly, inhibits presynaptic acetylcholine (Ach) release by preventing the fusion of Ach vesicles with the plasma membrane.” NCT06583343 ↗ “Encouraging results were reported with the use of botulinum neurotoxin-A (BoNT-A).” PMID 26808752 ↗ Sep 2016 “Comparison of Two Botulinum Neurotoxin A Injection Patterns” PMID 26885381 ↗ Jan 2016 |
| Known as | Botulinum Toxin | “Botulinum toxin or Botox, as it is commonly called, has the potential to temporarily reduce the tension in the muscles without causing permanent damage.” NCT00624299 ↗6“This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children.” NCT00060957 ↗ “botulinum toxin (BoNT-A) interventions prospectively compared to find out the effect of BoNT-A injection on myofascial pain syndrome (MPS).” NCT06899438 ↗ “intramuscular injection of 100U botulinum toxin (BoNT-A) is a reasonable choice for the treatment of bladder overactivity in PD” NCT05997043 ↗ “Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug).” NCT05162300 ↗ “As an alternative to strabismus surgery, botulinum toxin (Botox) can be applied in extraocular muscles.” NCT03459092 ↗ “Botox (botulinum toxin)” NCT01412008 ↗ |
| Known as | Botulinum toxin (BTX) A | “50 units of Botulinum toxin (BTX) A” NCT02584686 ↗ |
| Known as | Botulinum toxin A | “The hypothesis is that therapeutic treatment of drooling in children with cerebral palsy consisting of a standardized rehabilitation treatment associated with a botulinum toxin...” NCT03616067 ↗149“This is a 12-week, prospective double-blinded, randomized, multicenter study of placebo, 120 Unit, and 240 unit of botulinum toxin A ( Dysport ® ) injection for patient with a...” NCT00258609 ↗ “This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis...” NCT03717961 ↗ “The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic...” NCT02674269 ↗ “This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.” NCT02165111 ↗ “Improvement in skin lesions after botulinum toxin A injections has previously been reported in some patients but no prospective interventional studies are available.” PMID 33602313 ↗ Feb 2021 “Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.” NCT01905137 ↗ “Data from previous studies suggest that botulinum toxin A has analgesic effects against peripheral neuropathic pain, but the quality of the evidence is low.” PMID 26947719 ↗ Mar 2016 “Botulinum toxin A is widely used to alleviate facial dynamic rhytides but is also believed to improve scar quality by reducing wound tension during healing.” PMID 25541942 ↗ Dec 2014 “Between 2004 and 2015, a total of 145 patients underwent botulinum toxin-A (BTX-A) injections to treat RP in case reports, retrospective or open studies.” NCT03717961 ↗ “injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.” NCT04220931 ↗ “Botulinum toxin A and placed will be injected near the neurovascular bundle at the A1 pulley in the palm of the hand using a total dosage 100 U per hand” NCT06460194 ↗ “Botulinum toxin A (BoNT-A) injection is one of the most widely used methods for hemifacial spasm (HFS) with high efficacy in controlling spasm.” PMID 27431279 ↗ Jul 2016 “Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead.” PMID 24910934 ↗ Aug 2014 “Several case reports show potential efficacy of Botulinum Toxin-A (BTX-A) in inducing remission of HS however, these studies are underpowered.” NCT06237465 ↗ “Intramuscular injections of botulinum toxin A (BoNT-A) have shown an analgesic effect on LBP in two previous randomized controlled studies.” PMID 29141611 ↗ Nov 2017 “A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.” NCT01177358 ↗ “Currently, one of the most effective treatments is the intramuscular injection of botulinum toxin A in the muscles of mastication.” NCT04722809 ↗ “Intradetrusor (bladder) Botulinum toxin A (BTA or Botox®) is a well-established treatment for urinary urgency incontinence (UUI).” NCT05308979 ↗ “Botulinum toxin-A (Botox-A) is used as pharmacologic agent not only for aesthetic purposes, but also for its vasomotor actions.” PMID 27997734 ↗ Jan 2017 “Botulinum Toxin A (BTX-A): Botulinum toxin therapy is well-established for use in excessive sweating of several body areas” NCT03236012 ↗ “injections of botulinum toxin A (Botox) as the treatment for knee flexion contracture after total knee arthroplasty (TKA)” NCT01829087 ↗ “A thirty units of Botulinum toxin A was injected intramuscularly in Triger zone of patient with myofascial pain syndrome” NCT06824324 ↗ “Botulinum toxin-A (BTX-A) prevents the release of acetylcholine in presynaptic terminals of the neuromuscular junction.” NCT00992108 ↗ “Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial” NCT00194610 ↗ “Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points” NCT04940143 ↗ “stomach injections of botulinum toxin A (BTA), delivered through an endoscope using endoscopic ultrasound (EUS)” NCT00976443 ↗ “BOTOX® 100 U, botulinum toxin A injections in each hand or foot, for a final dose of 50 U (1 ml) per extremity” NCT05698979 ↗ “Botulinum Toxin A (BtxA) injected in spastic muscles has been shown to be effective in reducing muscle tone” PMID 10946168 ↗ Jul 2000 “INTERVENTIONS: Intramuscular botulinum toxin-A (Dysport 500-1000U) or placebo given at 0 and 12 weeks.” PMID 20111849 ↗ Jan 2010 “physicians were using botulinum toxin A (BTX-A) as a modality for prevention and treatment of keloids” NCT06230146 ↗ “One potential treatment for localized severe muscle pain involves injections with botulinum toxin A.” NCT00971620 ↗ “Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease” NCT05997043 ↗ “Botulinum toxin A has been used in recent studies precisely to improve the appearance of scars.” NCT06465056 ↗ “injection of botulinumtoxinA (AbobotulinumtoxinA /Dysort) into the gastrocnemius (calf) muscle” NCT03978234 ↗ “Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1.” NCT00989768 ↗ “Intramuscular injection of botulinum toxin A (BTA) induces reversible flaccid paralysis” NCT06499324 ↗ “Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.” NCT01678053 ↗ “Botulinum Toxin A (BTX-A) BTX-A is a neurotoxin produced by Clostridium botulinum” NCT06839118 ↗ “Botulinum toxin A is an FDA approved product for the treatment of hyperhidrosis.” NCT03203174 ↗ “Botulinum toxin-A will be injected into the spastic muscles with Stumplex.” NCT05627921 ↗ “Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb.” NCT01500668 ↗ “One group with 0,9% saline and the other Botulinum Toxin A.” NCT01357798 ↗ “Botulinum toxin A (Btx- A) is a highly effective treatment” NCT00432055 ↗ “botulinum toxin A injections in the rectus femoris” NCT02114736 ↗ “Agent: botulinum toxin A (BTX-A).” NCT07270042 ↗ “100 units Botulinum Toxin A” NCT00812838 ↗ “Botulinum Toxin A (Botox )” NCT00231491 ↗ “Botulinum Toxin A (Botox)” NCT01556971 ↗ “Botulinum toxin A” NCT02505802 ↗ |
| Known as | Botulinum Toxin A (BoNT-A) | “Botulinum Toxin A (BoNT-A)” NCT01733290 ↗ |
| Known as | Botulinum toxin type A (150 kD), free from complexing proteins | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins'” NCT00430963 ↗ |
| Known as | Botulinum toxin type A (150 kiloDalton), free from complexing proteins | “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT01515371 ↗3“NT 201 (Xeomin®, also know as IncobotulinumtoxinA or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT00541905 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT00432666 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT01603459 ↗ |
| Known as | Botulinum toxin type A (150kD), free of complexing proteins | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:” NCT00541723 ↗ |
| Known as | Botulinum Toxin Type A (BoNT-A) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06811142 ↗ |
| Known as | Botulinum toxin type A (Botox) | “Botulinum toxin type A (Botox)” NCT00908050 ↗ |
| Known as | Botulinum Toxin Type A 900kDa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00761592 ↗ |
| Known as | botulinum toxin type A [150 kDa] | “incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free from complexing proteins, or previously as NT 201)” PMID 22010053 ↗ Oct 2011 |
| Known as | Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) | “Botulinum toxin type A for injection (Hengli National Drug approval number S10970037)” NCT06196606 ↗1“Botulinum toxin type A for injection (Hengli National Drug approval number S10970037)” NCT06213662 ↗ |
| Known as | Botulinum Toxins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02168634 ↗ |
| Known as | Botulinum Toxn Type A | “Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin” NCT00549341 ↗ |
| Known as | Botulinum Type A | “Drug: Botulinum Type A” NCT01429402 ↗ |
| Known as | Botulinum-A neurotoxin | “Botulinum-A neurotoxin (BTX-A) has been shown in pilot trials to be quite effective in reducing overactive bladder symptoms” NCT01421719 ↗ |
| Known as | botulinum-A toxin | “intra-detrusor injections of botulinum-A toxin (BTX-A) in 20 male or female patients with Parkinson's disease and neurogenic overactive bladder” NCT01421719 ↗8“Botulinum-A toxin is a selective blocker of acetylcholine release from nerve endings and inhibits neural transmission when injected into muscle” NCT06851598 ↗ “Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking” NCT00175669 ↗ “A multi-center clinical trial of Botulinum-A Toxin (Botox) for refractory urge incontinence.” NCT00345332 ↗ |
| Known as | BTA | “The main objective of this prospective, open, uncontrolled pilot study was to investigate the safety of administering onabotulinumtoxinA (BTA) towards the sphenopalatine...” PMID 34633904 ↗ Oct 202113“Forty patients with stroke with spasticity in a functionally useless arm (median duration 3.1 years) were randomised to receive intramuscular botulinum toxin type A (BT-A;...” PMID 10896696 ↗ Aug 2000 “To investigate the efficacy and safety of injecting onabotulinum toxin A (BTA) towards the sphenopalatine ganglion (SPG) using the MultiGuide® in patients with persistent...” PMID 37435807 ↗ Jul 2023 “The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of...” NCT00822926 ↗ “botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia.” NCT06470581 ↗ “Recent studies have suggested that intra-articular injection of botulinum toxin A (BTA) may have analgesic effects in degenerative joint diseases.” PMID 29961037 ↗ Jun 2018 “Intradetrusor (bladder) Botulinum toxin A (BTA or Botox®) is a well-established treatment for urinary urgency incontinence (UUI).” NCT05308979 ↗ “stomach injections of botulinum toxin A (BTA), delivered through an endoscope using endoscopic ultrasound (EUS)” NCT00976443 ↗ “IL botulinum toxin type A (BTA) has been postulated in such an indication with controversial reports.” PMID 25810045 ↗ Mar 2015 “Intramuscular injection of botulinum toxin A (BTA) induces reversible flaccid paralysis” NCT06499324 ↗ “Botulinum toxin type A ( BTA) to prevent hypertrophic scar in median sternotomy wound” NCT02886988 ↗ “administering onabotulinumtoxinA (BTA) towards the sphenopalatine ganglion (SPG)” PMID 26232105 ↗ Jul 2015 “participants will receive Botulinum Toxin type A (BTA) injection.” NCT05072821 ↗ |
| Known as | BTX | “The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard...” NCT05512039 ↗8“To evaluate the clinical effectiveness of botulinum toxin (BTX) injection into the gastrocnemius muscles in patients with lumbar spinal stenosis (LSS) who have frequent...” PMID 28209505 ↗ Feb 2017 “The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic...” NCT02674269 ↗ “This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children.” NCT00060957 ↗ “This is a two cohort, randomized, double blind, single center study to evaluate the effects of Botox Cosmetic (BTX) on sebum protection.” NCT05138835 ↗ “Because of these findings, it has been proposed that a longer-lasting effect could be obtained with the use of OnabotulinumtoxinA (BTX).” NCT05112081 ↗ “patients received from 1 to 4 injections of botulinum toxin with LA (BTX) or LA alone.” PMID 31981833 ↗ Jan 2020 “botulinum toxin A (BTX) would improve rates of primary fascial closure” PMID 26813298 ↗ Feb 2016 “botulinum toxin A (BTX) adds a favourable effect” NCT01590693 ↗ |
| Known as | BTX A | “Since its introduction in the 1970s for the treatment of strabismus, blepharospasm, and focal dystonia, botulinum toxin type A (BTX-A) has been widely used in the treatment of...” NCT03555916 ↗40“Botulinum toxin A (BTX-A) treatment for glabellar frown lines and crow's feet of a lady who has also periocular vitiligo, we noted gradual and complete resolution of the...” NCT01051687 ↗ “Botulinum Toxin-A (BTX-A) has been increasingly used for the management of bruxism because of its ability to reduce masticatory muscle activity through inhibition of...” NCT07640035 ↗ “Botulinum toxin type A (BTX-A; Botox, Allergan, Inc., Irvine, CA, USA) was administered through intramuscular injection into the masseter and temporalis muscles during a single...” NCT07361900 ↗ “Evidence has been arising suggesting that Botulinum toxin type A (BTX-A) injections can relax smooth muscles fibers in the treatment of obesity and Detrusor muscle over-activity” NCT03355963 ↗ “Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation.” PMID 18546285 ↗ Sep 2008 “This study aims to evaluate the effectiveness of onabotulinum toxin A (BTX-A) in patients with MMD who have not responded to conventional non-invasive treatments.” NCT06840730 ↗ “The purpose of the meta-analysis was to evaluate the efficiency of therapeutic botulinum toxin type A (BTX-A) in the prevention of maxillofacial and neck scars.” PMID 26985661 ↗ Mar 2016 “Between 2004 and 2015, a total of 145 patients underwent botulinum toxin-A (BTX-A) injections to treat RP in case reports, retrospective or open studies.” NCT03717961 ↗ “OnabotulinumtoxinA (BTX-A) is an effective treatment for overactive bladder (OAB), but few studies have been done to evaluate injection techniques.” PMID 38484251 ↗ Mar 2024 “To assess the effect of Botulinum Toxin Type A (BTX-A) injections into the scalene muscles on pain, paresthesias and function in subjects with TOS.” NCT00444886 ↗ “Several case reports show potential efficacy of Botulinum Toxin-A (BTX-A) in inducing remission of HS however, these studies are underpowered.” NCT06237465 ↗ “BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s).” NCT03631966 ↗ “Botulinum toxin type A (BTXA) injection is a well established, clinically effective and safe treatment for muscle spasticity in CP (2;19;20).” NCT01437644 ↗ “Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).” NCT02555982 ↗ “Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy” NCT01421719 ↗ “Botulinum toxin-A (BTX-A) prevents the release of acetylcholine in presynaptic terminals of the neuromuscular junction.” NCT00992108 ↗ “50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally” NCT05980559 ↗ “administration of botulinum toxin type A (BTX-A) to the orbicularis oculi muscles of patients with keratoconus” PMID 28591280 ↗ Mar 2017 “Botulinum Toxin A (BtxA) injected in spastic muscles has been shown to be effective in reducing muscle tone” PMID 10946168 ↗ Jul 2000 “Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation” NCT06437912 ↗ “potential performance of incobotulinumtoxin-A (BTXA) in patients submitted to TMJ surgical arthroscopy.” NCT04810429 ↗ “physicians were using botulinum toxin A (BTX-A) as a modality for prevention and treatment of keloids” NCT06230146 ↗ “For the first session, the injection consisted of 100 units of BTX-A reconstituted in 4 ml of PRP.” NCT07335367 ↗ “Botulinum toxin type A (BTX-A) has achieved gratifying results in the treatment of dyskinesia.” NCT04939909 ↗ “Botulinum type A (BTX-A) is an easy and efficacious treatment for gingival smile (GS).” NCT04820543 ↗ “hypersensitivity to botulinum toxin A (BTX-A) or constituent ingredients of BTX-A” NCT01682603 ↗ “Botulinum Toxin A (BTX-A) BTX-A is a neurotoxin produced by Clostridium botulinum” NCT06839118 ↗ “Specifically, we will study botulinum toxin type A BTX-A, brand name Botox.” NCT03236012 ↗ “botulinum toxin type A (Btx-A) injections for Raynaud's phenomenon” NCT01309802 ↗ “Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/)” NCT03097835 ↗ “botulinum toxin injection (BTX A) before surgical intervention” NCT07137234 ↗ “Botulinum toxin type A (BTX-A) in a small group of patients” NCT01251211 ↗ “Botulinum toxin A (Btx- A) is a highly effective treatment” NCT00432055 ↗ “botulinum toxin type A (BTX-A) or placebo” NCT04750291 ↗ “Incobotulinumtoxin A (BTX A) Xeomin®” NCT04792398 ↗ “Dysport® (Botulinumtoxin A (Btx A))” NCT00936533 ↗ “Agent: botulinum toxin A (BTX-A).” NCT07270042 ↗ “Botulinum toxin type A (Btx-A)” NCT00279903 ↗ “botulinum toxin A (BTX-A)” NCT00900666 ↗ |
| Known as | BTX-A-HAC | “Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG))” NCT02353871 ↗ |
| Known as | Clostridium Botulinum A Toxin | “Botox (Clostridium Botulinum A Toxin)” NCT01629875 ↗ |
| Known as | Clostridium Botulinum Toxin Type A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03517319 ↗ |
| Known as | clostridium botulinum toxin type A neurotoxin complex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00934687 ↗ |
| Known as | Clostridium botulinum type A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03715777 ↗ |
| Known as | CORETOX Inj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04281745 ↗ |
| Known as | DAXI | “DaxibotulinumtoxinA (DAXI), a novel botulinum neurotoxin (BoNT) formulation, was shown to be safe, effective, and long-lasting in the treatment of cervical dystonia (CD) over...” PMID 40439027 ↗ May 20256“This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for...” NCT03825315 ↗ “BACKGROUND: SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development...” PMID 32773447 ↗ Jan 2021 “To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines.” PMID 36533798 ↗ Nov 2022 “Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)” NCT03786770 ↗ “DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development.” PMID 31791824 ↗ Nov 2019 “daxibotulinumtoxinA (DAXI) for injection” NCT02706795 ↗ |
| Known as | DAXI for Injection | “DaxibotulinumtoxinA for Injection (DAXI for Injection)” NCT03911102 ↗ |
| Known as | DaxibotulinumtoxinA | “DaxibotulinumtoxinA (DAXI) for injection is a sterile, lyophilized powder containing 100 units of active daxibotulinumtoxinA per vial, along with inactive ingredients including...” NCT07489430 ↗16“BACKGROUND: SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development...” PMID 32773447 ↗ Jan 2021 “The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.” NCT03137407 ↗ “DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA” NCT03821402 ↗ “DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)” NCT03825315 ↗ “DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development.” PMID 31791824 ↗ Nov 2019 “Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A.” PMID 33065952 ↗ Dec 2017 “DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis” NCT02973269 ↗ |
| Known as | DaxibotulinumtoxinA for injection | “DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be...” NCT03608397 ↗ |
| Known as | daxibotulinumtoxinA-lanm | “To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines.” PMID 36533798 ↗ Nov 2022 |
| Known as | daxibotuliumtoxinA | “Injectible daxibotuliumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and...” NCT05158166 ↗ |
| Known as | DAXXIFY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06411002 ↗ |
| Known as | DWP-450 (Botulinum purified neurotoxin, Type A) Injection | “DWP-450 (Botulinum purified neurotoxin, Type A) Injection” NCT02334436 ↗1“DWP-450 (Botulinum purified neurotoxin, Type A) Injection” NCT02334423 ↗ |
| Known as | DWP450 | “Botulinum toxin type A(DWP450)” NCT03369990 ↗1“DWP450: Botulinum toxin type A” NCT01945684 ↗ |
| Known as | Dysort | “injection of botulinumtoxinA (AbobotulinumtoxinA /Dysort) into the gastrocnemius (calf) muscle” NCT03978234 ↗ |
| Known as | Dysport | “This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the...” NCT03639766 ↗38“The aim of this study is to prospectively compare the clinical efficacy of Dry Needling (DN), Nabota (PrabotulinumtoxinA), and Dysport (AbobotulinumtoxinA) treatments on the...” NCT07452510 ↗ “Forty patients with stroke with spasticity in a functionally useless arm (median duration 3.1 years) were randomised to receive intramuscular botulinum toxin type A (BT-A;...” PMID 10896696 ↗ Aug 2000 “The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport((R)), Ipsen Biopharm Ltd.) for the...” PMID 20359934 ↗ Mar 2010 “This is a 12-week, prospective double-blinded, randomized, multicenter study of placebo, 120 Unit, and 240 unit of botulinum toxin A ( Dysport ® ) injection for patient with a...” NCT00258609 ↗ “The most commonly used subtype is toxin A commercially found as BOTOX (onabotulinumtoxinA, Allergan, approved by FDA in 1989), Dysport (abobotulinumtoxinA, Medicis, approved by...” NCT03186001 ↗ “Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic...” NCT03704155 ↗ “This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in...” NCT03469999 ↗ “The principal aim will be the pain evaluation (Visual Analogue Scale and McGill pain scale) with the use of 200 units of abobotulinumtoxin (Dysport) against placebo in both...” NCT04470401 ↗ “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of...” PMID 25476727 ↗ Dec 2014 “This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis.” NCT03935295 ↗ “Patients were randomised to receive either 300 units of AbobotulinumtoxinA (Dysport®) or 100 units of IncobotulinumtoxinA (Xeomin®).” NCT06250543 ↗ “Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers.” NCT06047444 ↗ “Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome” NCT00149240 ↗ “Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice” NCT04595045 ↗ “A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor” NCT03136341 ↗ “Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1.” NCT00959907 ↗ “DESIGN: Post hoc analysis from a phase 3 study of abobotulinumtoxinA (Dysport®, NCT01251367).” PMID 31529136 ↗ Oct 2019 “intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg)” NCT01473277 ↗ “Botulinum Toxin Type a (Dysport®, Abobotulinum Toxin A) Injection” NCT02917967 ↗ “AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.)” NCT06946160 ↗ “Botulinum Toxin Type A (Dysport®)” NCT00989768 ↗ “Botulinum Toxin Type A (Dysport®)” NCT07586072 ↗ “Botulinum Toxin Type A (Dysport®)” NCT07526870 ↗ |
| Known as | Dysport (abobotulinumtoxinA) | “Dysport® (abobotulinumtoxinA)” NCT03508869 ↗ |
| Known as | Dysport (abobotulinumtoxinA)injection | “Dysport® (abobotulinumtoxinA)injection” NCT00950664 ↗ |
| Known as | ET-01 | “This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).” NCT04985916 ↗ |
| Known as | GSK1358820 | “GSK1358820 (Botulinum Toxin Type A)” NCT01205451 ↗1“Botulinum toxin A (GSK1358820)” NCT03261167 ↗ |
| Known as | HU-014 | “Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.” NCT05964257 ↗ |
| Known as | HU-045 | “HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short...” NCT06205797 ↗ |
| Known as | iBonT-A | “1 dose of 20 units of incobotulinum toxin A (IBoNT/A) into the glabellar region (GR).” PMID 40434770 ↗ Jul 20251“perineural incobotulinumtoxin-A (iBonT-A) or placebo injections” NCT05623111 ↗ |
| Known as | INA | “IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.” NCT03571334 ↗ |
| Known as | incabotulinumtoxinA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01968902 ↗ |
| Known as | inco-BoNT-A | “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 20231“repeated injections of incobotulinumtoxinA (incoBoNT/A) for treatment of chronic sialorrhea” PMID 34341153 ↗ Oct 2021 |
| Known as | IncoA | “One-hundred units of Incobotulinumtoxin A (IncoA) or normal saline were injected into tibialis anterior, gastrocnemius, and biceps femoris muscles each side.” PMID 30274305 ↗ Sep 20181“OBJECTIVE: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA)” PMID 28789780 ↗ Aug 2017 |
| Known as | Incobotulinum toxin | “2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule” NCT06788158 ↗ |
| Known as | incobotulinumtoxin A | “The aim of this study is to confirm efficacy and safety of NT 201 (Xeomin®, also known as IncobotulinumtoxinA) after one injection session and to determine the efficacy and...” NCT00541905 ↗80“Neuromuscular retraining therapy and ipsilateral chemodenervation into discoordinated muscles by injection (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin,...” NCT04148872 ↗ “IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of...” NCT01896895 ↗ “The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus with use...” NCT05650645 ↗ “This is a double-blind, placebo-controlled study evaluating the safety and efficacy of incobotulinumtoxinA (Merz) for the treatment of provoked vestibulodynia (PVD) associated...” NCT07486830 ↗ “The open-label phase 3 "Treatment with IncobotulinumtoxinA in Movement Open-Label" (TIMO) study investigated longer-term safety and efficacy of incobotulinumtoxin A in...” PMID 34957963 ↗ 2022 “Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to...” PMID 40971935 ↗ Nov 2025 “The authors sought to compare the newest U.S. Food and Drug Administration-approved botulinum toxin type A product, incobotulinumtoxinA, to onabotulinumtoxinA for upper face wrinkles.” PMID 25919246 ↗ May 2015 “Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).” NCT03977493 ↗ “For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected.” NCT05027243 ↗ “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 “One-hundred units of Incobotulinumtoxin A (IncoA) or normal saline were injected into tibialis anterior, gastrocnemius, and biceps femoris muscles each side.” PMID 30274305 ↗ Sep 2018 “The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions.” NCT01931878 ↗ “A newer method of treating plantar fasciitis before resorting to surgery is the use of Botulinum Toxin or Xeomin (incobotulinum toxin A, Merz USA).” NCT01678001 ↗ “incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free from complexing proteins, or previously as NT 201)” PMID 22010053 ↗ Oct 2011 “XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage.” NCT04810429 ↗ “Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.” NCT02270736 ↗ “50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally” NCT05980559 ↗ “potential performance of incobotulinumtoxin-A (BTXA) in patients submitted to TMJ surgical arthroscopy.” NCT04810429 ↗ “Evaluate safety and efficacy of Incobotulinumtoxin A in elderly patients with dementia and paratonia.” PMID 25536218 ↗ Dec 2014 “1 dose of 20 units of incobotulinum toxin A (IBoNT/A) into the glabellar region (GR).” PMID 40434770 ↗ Jul 2025 “incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments.” NCT03048383 ↗ “botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH” NCT04075981 ↗ “NT 201 (IncobotulinumtoxinA/Xeomin®)” NCT00507637 ↗ “Other Names: IncobotulinumtoxinA” NCT06205797 ↗ “IncobotulinumtoxinA: 20 units” NCT06448676 ↗ “incobotulinumtoxinA (Xeomin®)” NCT04970407 ↗ |
| Known as | incobotulinumtoxinA (Xeomin) | “incobotulinumtoxinA (Xeomin®)” NCT04970407 ↗1“incobotulinumtoxinA (Xeomin)” NCT02122536 ↗ |
| Known as | MEDITOXIN | “PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm.” PMID 19794937 ↗ Sep 200915“injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses” NCT03317717 ↗ “MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity” NCT01313767 ↗ “injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses” NCT03647982 ↗ “The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy” NCT01256021 ↗ “Botulinum Toxin Type A(Meditoxin®)” NCT01237977 ↗ |
| Known as | Medy-Tox | “PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm.” PMID 19794937 ↗ Sep 2009 |
| Known as | Medytoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03905304 ↗ |
| Known as | Mentor Purified Toxin | “The safety and efficacy of Mentor Purified Toxin, Botulinum Toxin Type A, Purified Neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for...” NCT00549341 ↗ |
| Known as | microtoxin | “microdoses of botulinum toxin type A (microtoxin)” NCT07526870 ↗ |
| Known as | Nabota | “ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle” NCT02444351 ↗ |
| Known as | NeurOtoxin | “Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study.” PMID 34687654 ↗ Oct 2021 |
| Known as | NT 201 | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin...” NCT00770211 ↗23“IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT01515371 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT00407030 ↗ “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:” NCT00541723 ↗ “Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0.” NCT00430586 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT00432666 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT01603459 ↗ “IncobotulinumtoxinA, also known as NT 201, is a new botulinum toxin type A (150 kDa) that is free from complexing proteins.” PMID 21134045 ↗ Dec 2010 “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins'” NCT00430963 ↗ “NT 201 (IncobotulinumtoxinA/Xeomin®)” NCT00507637 ↗ |
| Known as | OBoNT | “To compare the efficacy and safety of DWP450 with onabotulinumtoxinA (OBoNT) for use in the treatment of glabellar lines, we performed a multicenter, double-blind, randomized,...” PMID 25311357 ↗ Oct 2014 |
| Known as | OBoNT/A | “1 dose of 20 units of onabotulinum toxin A (OBoNT/A);” PMID 40434770 ↗ Jul 2025 |
| Known as | OBTA | “OnabotulinumtoxinA (OBTA) is approved for treating chronic headaches and migraines in adults” PMID 33106278 ↗ Oct 2020 |
| Known as | ONA | “BACKGROUND AND OBJECTIVE: To evaluate the efficacy and safety of onabotulinumtoxinA (ONA) injections to the depressor anguli oris (DAO) to improve downturned mouth.” PMID 36763899 ↗ Feb 20231“Drug: OnabotulinumtoxinA (ONA)” NCT01732809 ↗ |
| Known as | ona-BoNT-A | “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 20234“Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).” NCT02009540 ↗ |
| Known as | OnaA | “Background: OnabotulinumtoxinA (OnaA) injection in glabella area appears to be a promising treatment for major depression.” PMID 40226647 ↗ Sep 2024 |
| Known as | onabotA | “This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major...” PMID 31609787 ↗ Jan 20202“botulinum toxin type A (onabotulinumtoxinA; onabotA) injections to induce temporary paralysis in the glabellar muscles” PMID 36849797 ↗ Feb 2023 “onabotulinumtoxinA (onabotA) for moderate or severe PP.” PMID 41933889 ↗ Apr 2026 |
| Known as | onabotulinum toxin type-A | “Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy” NCT01421719 ↗ |
| Known as | onabotulinum toxin-A | “The main objective of this prospective, open, uncontrolled pilot study was to investigate the safety of administering onabotulinumtoxinA (BTA) towards the sphenopalatine...” PMID 34633904 ↗ Oct 2021190“OBJECTIVE: The aim of this multicentre, double-blind, randomized, parallel, active-controlled Phase III clinical trial with two stages (ClinicalTrials.gov identifier:...” PMID 33721365 ↗ Apr 2021 “Treatment consisted of a multimodal approach including intravaginal injections of onabotulinumtoxinA (Botox) and bupivacaine, progressive dilation under conscious sedation,...” PMID 28363809 ↗ Mar 2017 “METHODS: In this Phase 2, randomized, dose-ranging, parallel-group, double-blind, multicenter study, subjects with moderate or severe glabellar lines at maximum frown were...” PMID 28614091 ↗ Nov 2017 “To compare the efficacy and safety of DWP450 with onabotulinumtoxinA (OBoNT) for use in the treatment of glabellar lines, we performed a multicenter, double-blind, randomized,...” PMID 25311357 ↗ Oct 2014 “Neuromuscular retraining therapy and ipsilateral chemodenervation into discoordinated muscles by injection (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin,...” NCT04148872 ↗ “The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard...” NCT05512039 ↗ “The BTX-A group will receive onabotulinumtoxinA (Botox®, Allergan) with mandatory muscles getting 300 units and optional muscles getting up to 100 additional units (maximum...” NCT06296082 ↗ “In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation...” NCT05874154 ↗ “OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind,...” PMID 22464310 ↗ Mar 2012 “To investigate the efficacy and safety of injecting onabotulinum toxin A (BTA) towards the sphenopalatine ganglion (SPG) using the MultiGuide® in patients with persistent...” PMID 37435807 ↗ Jul 2023 “Lack of head-to-head comparative safety and efficacy data for abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) represented an important gap for informed...” PMID 42159955 ↗ May 2026 “Evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox®) in chronic migraine (CM) patients is maintained over long term treatment is...” NCT03606356 ↗ “Intradetrusor injection of onabotulinumtoxinA, 100 U (treatment focused on the urgency component), vs surgical synthetic mesh midurethral sling (treatment focused on the stress...” PMID 40323617 ↗ Jun 2025 “For the treatment B arm one vial of ONABOTULINUMTOXINA 200 UNITS/VIAL for each subject will be drawn in two separate syringes of 100 units each and reconstituted with the 1% lidocaine.” NCT03616262 ↗ “The authors sought to compare the newest U.S. Food and Drug Administration-approved botulinum toxin type A product, incobotulinumtoxinA, to onabotulinumtoxinA for upper face wrinkles.” PMID 25919246 ↗ May 2015 “The objective of this study was to compare efficacy and adverse events between 100 U and 200 U of onabotulinumtoxinA for 6 months in women with nonneurogenic urgency incontinence.” PMID 33620895 ↗ Mar 2021 “Botox, (onabotulinumtoxin A) a drug derived from a Botulinum toxin, interferes with the chemical transmitter, acetylcholine, that is responsible for muscle contraction or spasm .” NCT06755099 ↗ “100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.” NCT04401176 ↗ “OBJECTIVE: To investigate the safety of injecting onabotulinumtoxin A (BTA) toward the OG in 10 patients with intractable chronic cluster headache and to collect efficacy data.” PMID 32583902 ↗ Jun 2020 “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 “The objective of the study was to compare the effect of onabotulinumtoxin A vs placebo injections to the pelvic floor muscles in women with myofascial pelvic pain.” PMID 31254522 ↗ Jun 2019 “This study aims to evaluate the effectiveness of onabotulinum toxin A (BTX-A) in patients with MMD who have not responded to conventional non-invasive treatments.” NCT06840730 ↗ “INTERVENTION: Patients were randomised to undergo a single intradetrusor injection procedure of either placebo or onabotulinumtoxinA (50 U, 100 U or 150 U).” PMID 22036776 ↗ Oct 2011 “We evaluated the efficacy and safety of Neuronox (Neu-BoNT/A) compared with BOTOX (onabotulinum toxin A) for treating post-stroke upper limb spasticity.” PMID 26030192 ↗ Jun 2015 “Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.” NCT02074163 ↗ “This multicenter, open-label, Phase IV study evaluated GL treatment experience using RTU abobotulinumtoxinA versus powder BoNT-A (onabotulinumtoxinA).” PMID 38807515 ↗ May 2024 “To compare the efficacy and safety of MT10107 (Coretox) with those of onabotulinum toxin A (Botox) in patients with poststroke upper limb spasticity” PMID 32497599 ↗ Jun 2020 “OnabotulinumtoxinA (BTX-A) is an effective treatment for overactive bladder (OAB), but few studies have been done to evaluate injection techniques.” PMID 38484251 ↗ Mar 2024 “To investigate the safety of injecting onabotulinumtoxinA (BTA) toward the SPG using the MultiGuide® in 10 patients with refractory classical TN” PMID 31342515 ↗ Jul 2019 “Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead.” PMID 24910934 ↗ Aug 2014 “Phase 1b Safety and Tolerability of Intradermal BOTOX® (OnabotulinumtoxinA) Purified Neurotoxin Complex in Participants With Facial Fine Lines” NCT04631588 ↗ “To assess the effects of onabotulinumtoxinA (BOTOX(®), Allergan, Inc.) on UI, urodynamic variables, and QOL in incontinent patients with NDO.” PMID 21798658 ↗ Jul 2011 “Because of these findings, it has been proposed that a longer-lasting effect could be obtained with the use of OnabotulinumtoxinA (BTX).” NCT05112081 ↗ “A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.” PMID 23098762 ↗ Oct 2012 “OnabotulinumtoxinA treatment of 155 units or 195 units will be injected intramuscularly over 31-35 injections of head and neck muscles.” NCT05724771 ↗ “OBJECTIVE: To evaluate safety and efficacy of onabotulinumtoxinA (BOTOX(®) ) as headache prophylaxis in adults with chronic migraine.” PMID 21883197 ↗ Aug 2011 “Microbotox also called mesobotox, is the injection of multiple microdroplets of diluted onabotulinum toxin A into the upper dermis.” NCT05923996 ↗ “OnabotulinumtoxinA (Botox) 200u will be reconstituted using 4 ml of preservative-free saline, as recommended by the manufacturer.” NCT03698409 ↗ “This multicenter, double-blind, phase 2 study evaluated onabotulinumtoxinA treatment in adults with moderate to severe PP.” PMID 38640068 ↗ Apr 2024 “Background: OnabotulinumtoxinA (OnaA) injection in glabella area appears to be a promising treatment for major depression.” PMID 40226647 ↗ Sep 2024 “100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia.” PMID 21791356 ↗ Jul 2011 “There are no previous reports on the use of Onabotulinum Toxin A to treat men with scrotal pain that we found published.” NCT01832194 ↗ “OBJECTIVE: To evaluate the efficacy and safety of onabotulinumtoxinA in adolescents with primary axillary hyperhidrosis.” PMID 26059781 ↗ Jun 2015 “At the moment Onabotulinum toxin A (BoNT-A) represents the only drug specifically approved for CM prophylaxis.” NCT04578782 ↗ “Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections” NCT04020510 ↗ “OnabotulinumtoxinA 20 U (10 U per site) or 50 U (25 U per site) were randomly assigned to 70 adults with CAF” NCT07543315 ↗ “OnabotulinumtoxinA has shown a degree of usefulness in other conditions associated with neuropathic pain.” PMID 23740337 ↗ Jul 2013 “Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline” NCT00178646 ↗ “200 U intradetrusor injected OnabotulinumtoxinA (Botox®, Allergan, Inc.) (20 sites, trigone sparing)” NCT02298660 ↗ “OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.” PMID 23892704 ↗ Jul 2013 “FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.” PMID 35166150 ↗ Feb 2022 “Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC” NCT04383912 ↗ “All enrolled patients received intravesical injection of 100 U onabotulinumtoxinA (Botox).” PMID 26824901 ↗ Jan 2016 “40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each” NCT02070302 ↗ “OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration” NCT01553201 ↗ “OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.” NCT00894517 ↗ “administering onabotulinumtoxinA (BTA) towards the sphenopalatine ganglion (SPG)” PMID 26232105 ↗ Jul 2015 “Instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder” NCT02735499 ↗ “Two Botulinum Type A Exotoxins (Onabotulinum Toxin A and Abobotulinum Toxin A)” NCT01529788 ↗ “OnabotulinumtoxinA for Chronic Headaches: Is 155 Units Superior to 100 Units?” NCT04349176 ↗ “Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30” NCT02074150 ↗ “Participants will receive intravesical injection of onabotulinumtoxinA.” NCT07184307 ↗ “Injection of onabotulinumtoxinA into the at-risk major salivary glands” NCT06530524 ↗ “Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/)” NCT03097835 ↗ “Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6” NCT02074293 ↗ “Botox® (onabotulinumtoxin A),injections in the calf muscles.” NCT02546999 ↗ “Onabotulinum toxin A treatment of cervicogenic headache” PMID 21300635 ↗ Feb 2011 “1 dose of 20 units of onabotulinum toxin A (OBoNT/A);” PMID 40434770 ↗ Jul 2025 “Botox (onabotulinumtoxin A; Allergan, Inc., Ireland)” PMID 22385408 ↗ Apr 2012 “200U onabotulinumtoxinA (botox)” NCT01220726 ↗ “Onabotulinumtoxin A (Botox®)” PMID 29671033 ↗ Apr 2018 “OnabotulinumtoxinA: 20 units” NCT06448676 ↗ “onabotulinumtoxinA (Botox®)” NCT04970407 ↗ “OnabotulinumtoxinA (Botox®)” NCT02450526 ↗ “Drug: Onabotulinum Toxin A” NCT04401176 ↗ “OnabotulinumtoxinA” NCT05006417 ↗ |
| Known as | onabotulinumtoxinA (Botox) | “OnabotulinumtoxinA (Botox®)” NCT02450526 ↗ |
| Known as | onabotulinumtoxinA neurotoxin | “STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines?” NCT05766683 ↗ |
| Known as | OnBA | “OBJECTIVE: The aim of this multicentre, double-blind, randomized, parallel, active-controlled Phase III clinical trial with two stages (ClinicalTrials.gov identifier:...” PMID 33721365 ↗ Apr 2021 |
| Known as | onobotulinumtoxinA | “The standard BT injection will be an injection of 25 units of onobotulinumtoxinA (Botox®) diluted in 0.25cc of saline.” NCT03367429 ↗ |
| Known as | onobutilinumtoxinA | “The experimental BT injection will be an injection of 25 units of onobutilinumtoxinA (Botox®) diluted in 0.50cc of saline.” NCT03367429 ↗ |
| Known as | Prosigne | “Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia.” PMID 23468866 ↗ Feb 2013 |
| Known as | Refinex | “botulinum toxin type A (Refinex; 5 IU per side)” NCT07715331 ↗ |
| Known as | RT001 | “RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines” NCT00968825 ↗1“RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults” NCT01064518 ↗ |
| Known as | RT002 | “Injectable daxibotulinumtoxinA (an investigational botulinum toxin, RT002) may offer a more prolonged duration of response-and therefore less frequent dosing-than onabotulinumtoxinA.” PMID 30009213 ↗ Apr 20181“Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A.” PMID 33065952 ↗ Dec 2017 |
| Known as | type A botulinum toxin | “Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®,...” NCT07013240 ↗ |
| Known as | Vistabel | “A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections” NCT05647551 ↗2“OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units” NCT00777803 ↗ |
| Known as | Xeomeen | “IncobotulinumtoxinA (NT 201, Xeomin/Xeomeen/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) is a 150-kDa botulinum toxin type A free of complexing proteins.” PMID 23379292 ↗ Feb 2013 |
| Known as | XEOMIN | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin...” NCT00770211 ↗44“The aim of this study is to confirm efficacy and safety of NT 201 (Xeomin®, also known as IncobotulinumtoxinA) after one injection session and to determine the efficacy and...” NCT00541905 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT01515371 ↗ “It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment...” NCT06499324 ↗ “The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus with use...” NCT05650645 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT00407030 ↗ “Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults...” NCT06205797 ↗ “Botulinum toxin, such as incobotulinumtoxinA (XEOMIN, Merz herapeutics), have been shown to be effective and safe in relaxing these muscles in conditions like spasticity,...” NCT05536570 ↗ “Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).” NCT03977493 ↗ “NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).” NCT00777803 ↗ “Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure” NCT06345677 ↗ “Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin.” NCT00515944 ↗ “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:” NCT00541723 ↗ “Patients were randomised to receive either 300 units of AbobotulinumtoxinA (Dysport®) or 100 units of IncobotulinumtoxinA (Xeomin®).” NCT06250543 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT00432666 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT01603459 ↗ “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins'” NCT00430963 ↗ “XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage.” NCT04810429 ↗ “50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally” NCT05980559 ↗ “Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.” NCT02270736 ↗ “Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis” NCT03119948 ↗ “Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control” NCT03380559 ↗ “The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).” NCT05327972 ↗ “botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH” NCT04075981 ↗ “IncobotulinumtoxinA 100 UNT Injection [Xeomin]” NCT03758235 ↗ “Incobotulinumtoxin A (BTX A) Xeomin®” NCT04792398 ↗ “IncobotulinumtoxinA 100 UNT [Xeomin]” NCT05340439 ↗ “NT 201 (IncobotulinumtoxinA/Xeomin®)” NCT00507637 ↗ “IncobotulinumtoxinA (Xeomin ®)” NCT03044080 ↗ “Xeomin” NCT02088632 ↗ |
| Action | Inhibit | “Botulinum toxin should be able to inhibit salivary gland secretion by blocking the release of acetylcholine” NCT00173745 ↗ |
| Modality | Protein / enzyme biologic | “Biological: botulinum toxin Type A” NCT00076687 ↗ |
| Route | Other | “BTX injections” NCT00060957 ↗ |
| Target | SNAP25 | “specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25)” NCT02427646 ↗ |